



(51) International Patent Classification:

A61K 31/192 (2006.01) *A61P 3/00* (2006.01)
A61K 9/20 (2006.01) *A61P 3/08* (2006.01)
A61K 9/48 (2006.01) *C07C 57/30* (2006.01)

(21) International Application Number:

PCT/CA2019/051753

(22) International Filing Date:

05 December 2019 (05.12.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/775,849 05 December 2018 (05.12.2018) US

(71) Applicant: **LIMINAL BIOSCIENCES LIMITED**
[GB/GB]; Horizon Park, Barton Road, Comberton Cam-
bridgeshire CB23 7AJ (GB).

(72) Inventors: **GAGNON, Lyne**; 1973 rue de la Victoire,
Laval, Québec H7M 3E5 (CA). **LAURIN, Pierre**; 2250
Chemin Sunset, Ville Mont-Royal, Québec H3R 2Y6 (CA).
CESARI, Frank; 99 Cragmore, Pointe-Claire, Québec
H9R 3K7 (CA).

(74) Agent: **LAVERY, DE BILLY, L.L.P.**; 1, Place Ville
Marie, Bureau 4000, Montréal, Québec H3B 4M4 (CA).

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(54) Title: USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME




FIG. 3B

(57) Abstract: Methods, formulations/compositions and uses for improving at least one of liver histology, heart histology, kidney histology, adipose tissue histology and a metabolic parameter in a patient suffering from Alström syndrome are described, comprising administration of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient at a daily dose of about 500 mg to about 1500 mg. The treatment is preferably for a period of more than 48 weeks and is not interrupted for 15 days or more.



Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

USE OF SODIUM 2-(3-PENTYLPHENYL)ACETATE IN THE TREATMENT OF ALSTRÖM SYNDROME

CROSS REFERENCE TO RELATED APPLICATIONS

This application claims the benefit of U.S. provisional application serial No. 62/775,849,
5 filed on December 5, 2018, which is incorporated herein by reference in its entirety.

TECHNICAL FIELD

The present disclosure generally relates to the management of pathological features of Alström syndrome (ALMS).

BACKGROUND ART

10 ALMS is a rare autosomal recessive genetic disorder with an estimated prevalence of less than one per million. It is characterized by cone-rod dystrophy, hearing loss, childhood truncal obesity, insulin resistance and hyperinsulinemia, type 2 diabetes, hypertriglyceridemia, short stature in adulthood, cardiomyopathy, and progressive pulmonary, hepatic, and renal dysfunction. Symptoms first appear in infancy and progressive development of multi-organ pathology leads to
15 a reduced life expectancy. Variability in age of onset and severity of clinical symptoms, even within families, is likely due to genetic background. The severity of the disease, often leading to organ failure, results in a reduced life expectancy, rarely exceeding 50 years. The clinical care of individuals is complex due to the combination of multiple endocrine disorders, sensorineural deficits, cardiac, renal, and hepatic abnormalities. There is no specific therapy, and individuals
20 are treated and monitored on the basis of individual symptoms.

There is thus a need for novel therapeutic approaches for the management of ALMS.

The present description refers to a number of documents, the content of which is herein incorporated by reference in their entirety.

SUMMARY OF THE DISCLOSURE

25 The present disclosure relates to the management of pathological features of ALMS.

More specifically, in accordance with aspects and embodiments of the present disclosure, there are provided the following items:

1. A method for improving at least one of liver histology, heart histology, kidney histology, adipose tissue histology and glycemic control in a patient suffering from ALMS, said method
30 comprising administering to said patient a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg for a treatment period of more

than 48 weeks, and wherein the administration is not interrupted for 15 days or more during said treatment period.

2. The method of item 1, wherein the treatment period is of more than 54 weeks.
3. The method of item 1, wherein the treatment period is of more than 60 weeks.
- 5 4. The method of any one of items 1 to 3, wherein the administration is not interrupted for 30 days or more.
5. The method of any one of items 1 to 4, wherein said method is for improving at least liver histology.
6. The method of item 5, wherein improving liver histology comprises reducing liver stiffness.
- 10 7. The method of item 6, wherein the liver stiffness is reduced by at least 2 kPa relative to prior to the administration, as measured by transient elastography.
8. The method of item 7, wherein the liver stiffness is reduced by at least 2.25 kPa relative to prior to the administration, as measured by transient elastography.
9. The method of any one of items 5 to 8, wherein improving liver histology comprises reducing the Metavir score by at least one grade or stage.
- 15 10. The method of any one of items 1 to 9, wherein said method is for improving at least heart histology.
11. The method of any one of items 1 to 10, wherein improving heart histology comprises increasing left ventricular function (LVF).
- 20 12. The method of item 11, wherein the LVF comprises left ventricular end-diastolic volume (LVEDV) and/or left ventricular end-systolic volume (LVESV).
13. The method of item 11, wherein the LVF comprises LVEDV.
14. The method of item 12 or 13, wherein the method is for increasing LVEDV by at least 6 ml relative to prior to the administration, as measured by cardiac Magnetic Resonance Imaging (MRI).
- 25 15. The method of any one of items 10 to 14, wherein improving heart histology comprises reducing short-axis (plane) longitudinal relaxation time (SAX T1).

16. The method of item 15, wherein the SAX T1 is Basal SAX T1 and/or Mid SAX T1.
17. The method of item 16, wherein the method is for reducing Basal SAX T1 by at least 40 ms relative to prior to the administration, as measured by cardiac MRI.
18. The method of item 16 or 17, wherein the method is for reducing Mid SAX T1 by at least 25 ms relative to prior to the administration, as measured by cardiac MRI.
19. The method of any one of items 1 to 18, wherein said method is for improving at least kidney histology.
20. The method of any one of items 1 to 19, wherein improving kidney histology comprises restricting kidney damage or injury.
21. The method of item 19 or 20, wherein improving kidney histology comprises reducing the levels of one or more biomarkers of kidney injury relative to prior to the administration.
22. The method of item 21, wherein the one or more biomarkers of kidney injury are monocyte chemoattractant protein 1 (MCP-1), kidney injury molecule-1 (KIM-1), clusterin, cystatin C and osteopontin.
23. The method of item 22, wherein the method is for reducing the levels of said one or more biomarkers by at least 10%.
24. The method of any one of items 1 to 23, wherein said method is for improving at least adipose tissue histology.
25. The method of item 24, wherein improving adipose tissue histology comprises reducing average adipocyte area.
26. The method of item 25, wherein the method is for reducing average adipocyte area by at least 10%.
27. The method of any one of items 1 to 26, wherein said method is for improving at least glycemic control.
28. The method of any one of items 1 to 27, wherein improving glycemic control comprises reducing glycated hemoglobin (HbA1c).
29. The method of item 28, wherein the subject has an HbA1c of more than 9% prior to administration.

30. The method of item 28 or 29, wherein the method is for reducing HbA1c by at least 1% (absolute).
31. The method of any one of items 1 to 30, wherein improving glycemic control comprises increasing the homeostasis Model Assessment for Steady State Beta-Cell Function Based on C-Peptide and Fasting Plasma Glucose (HOMA-B [C-Peptide/FPG]).
32. The method of item 31, wherein said method is for increasing HOMA-B [C-Peptide/FPG] by at least 20.
33. A method for improving glycemic control in an ALMS patient with diabetes, said method comprising administering to said patient a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
34. The method of item 33, wherein the patient has type 2 diabetes.
35. A method for improving liver function in an ALMS patient with liver disease, said method comprising administering to said patient a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
36. The method of item 35, wherein the liver disease comprises liver fibrosis.
37. The method of item 36, wherein the patient has fibrosis stage F2, F3 or F4 according to the Metavir scoring system.
38. A method for improving cardiac function in an ALMS patient, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
39. The method of item 38, wherein the cardiac function is left ventricular function (LVF) and/or short-axis (plane) longitudinal relaxation time (SAX T1).
40. The method of item 39, wherein the LVF comprises left ventricular end-diastolic volume (LVEDV) and/or left ventricular end-systolic volume (LVESV).

41. The method of item 39 or 40, wherein the patient has a lower than normal LVF.
42. The method of item 41, wherein (i) the patient is a male and has a LVEDV of less than 106 mL and/or a LVESV of less than 26 mL; or (ii) the patient is a female and has a LVEDV of less than 86 mL and/or a LVESV of less than 22 mL.
- 5 43. A method for improving kidney function in an ALMS patient suffering from kidney damage or injury, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
- 10
44. The method of item 43, wherein the patient has higher than normal levels of one or more biomarkers of kidney toxicity.
45. The method of item 44, wherein the one or more biomarkers of kidney injury are monocyte chemoattractant protein 1 (MCP-1), kidney injury molecule-1 (KIM-1), clusterin, cystatin C and osteopontin.
- 15
46. A method for improving adipose tissue function in an ALMS patient, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
- 20
47. The method of item 46, wherein the adipose tissue function is perivascular adipose tissue function.
48. The method of any one of items 33 to 47, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 24 weeks.
- 25 49. The method of item 48, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 48 weeks.
50. The method of item 48, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 60 weeks.
51. The method of any one of items 1 to 50, wherein the daily dose is of about 700 mg to about 900 mg.
- 30

52. The method of item 51, wherein the daily dose is of about 800 mg.
53. The method of any one of items 1 to 50, wherein the daily dose is of about 1100 mg to about 1300 mg.
54. The method of item 53, wherein the daily dose is of about 1200 mg.
- 5 55. The method of any one of items 1 to 54, wherein the pharmaceutical oral formulation comprises sodium 2-(3-pentylphenyl)acetate.
56. The method of any one of items 1 to 55, wherein the pharmaceutical oral formulation is a capsule or a tablet.
57. The method of any one of items 1 to 56, wherein the subject has a body mass index (BMI) $\geq$
10 25.0 kg/m².
58. The method of any one of items 1 to 57, wherein the subject is a male and has a waist circumference $\geq$ 94 cm, or the subject is a female and has a waist circumference $\geq$ 80 cm.
59. A pharmaceutical oral formulation for use in improving at least one of liver histology, heart histology, kidney histology, adipose tissue histology and glycemic control in a patient suffering
15 from ALMS, the pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg for a treatment period of more than 48 weeks, and wherein the administration is not interrupted for 15 days or more during said treatment period.
- 20 60. The formulation for use of item 59, wherein the treatment period is of more than 54 weeks.
61. The formulation for use of item 59, wherein the treatment period is of more than 60 weeks.
62. The formulation for use of any one of items 59 to 61, wherein the administration is not interrupted for 30 days or more.
63. The formulation for use of any one of items 59 to 62, wherein said method is for improving at
25 least liver histology.
64. The formulation for use of item 63, wherein improving liver histology comprises reducing liver stiffness.
65. The formulation for use of item 64, wherein the liver stiffness is reduced by at least 2 kPa relative to prior to the administration, as measured by transient elastography.

66. The formulation for use of item 65, wherein the liver stiffness is reduced by at least 2.25 kPa relative to prior to the administration, as measured by transient elastography.
67. The formulation for use of any one of items 63 to 68, wherein improving liver histology comprises reducing the Metavir score by at least one grade or stage.
- 5 68. The formulation for use of any one of items 59 to 67, wherein said method is for improving at least heart histology.
69. The formulation for use of any one of items 59 to 70, wherein improving heart histology comprises increasing left ventricular function (LVF)
- 10 70. The formulation for use of item 69, wherein the LVF comprises left ventricular end-diastolic volume (LVEDV) and/or left ventricular end-systolic volume (LVESV).
71. The formulation for use of item 70, wherein the LVF comprises LVEDV.
72. The formulation for use of item 70 or 71, wherein the method is for increasing LVEDV by at least 6 ml relative to prior to the administration, as measured by cardiac Magnetic Resonance Imaging (MRI).
- 15 73. The formulation for use of any one of items 68 to 71, wherein improving heart histology comprises reducing short-axis (plane) longitudinal relaxation time (SAX T1).
74. The formulation for use of item 73, wherein the SAX T1 is Basal SAX T1 and/or Mid SAX T1.
75. The formulation for use of item 74, wherein the method is for reducing Basal SAX T1 by at least 40 ms relative to prior to the administration, as measured by cardiac MRI.
- 20 76. The formulation for use of item 74 or 75, wherein the method is for reducing Mid SAX T1 by at least 25 ms relative to prior to the administration, as measured by cardiac MRI.
77. The formulation for use of any one of items 59 to 76, wherein said method is for improving at least kidney histology.
- 25 78. The formulation for use of any one of items 59 to 77, wherein improving kidney histology comprises restricting kidney damage or injury.
79. The formulation for use of item 77 or 78, wherein improving kidney histology comprises reducing the levels of one or more biomarkers of kidney injury relative to prior to the administration.

80. The formulation for use of item 79, wherein the one or more biomarkers of kidney injury are monocyte chemoattractant protein 1 (MCP-1), kidney injury molecule-1 (KIM-1), clusterin, cystatin C and osteopontin.
- 5 81. The formulation for use of item 80, wherein the method is for reducing the levels of said one or more biomarkers by at least 10%.
82. The formulation for use of any one of items 59 to 81, wherein said method is for improving at least adipose tissue histology.
83. The formulation for use of item 82, wherein improving adipose tissue histology comprises reducing average adipocyte area.
- 10 84. The formulation for use of item 83, wherein the method is for reducing average adipocyte area by at least 10%.
85. The formulation for use of any one of items 59 to 84, wherein said method is for improving at least glycemic control.
- 15 86. The formulation for use of any one of items 1 to 85, wherein improving glycemic control comprises reducing glycated hemoglobin (HbA1c).
87. The formulation for use of item 86, wherein the subject has an HbA1c of more than 9% prior to administration.
88. The formulation for use of item 86 or 87, wherein the method is for reducing HbA1c by at least 1% (absolute).
- 20 89. The formulation for use of any one of items 59 to 88, wherein improving glycemic control comprises increasing the homeostasis Model Assessment for Steady State Beta-Cell Function Based on C-Peptide and Fasting Plasma Glucose (HOMA-B [C-Peptide/FPG]).
90. The formulation for use of item 89, wherein said method is for increasing HOMA-B [C-Peptide/FPG] by at least 20.
- 25 91. A pharmaceutical oral formulation for use in improving glycemic control in an ALMS patient with diabetes, said pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

92. The formulation for use of item 91, wherein the patient has type 2 diabetes.

93. A pharmaceutical oral formulation for use in improving liver function in an ALMS patient with liver disease, said pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

94. The formulation for use of item 93, wherein the liver disease comprises liver fibrosis.

95. The formulation for use of item 94, wherein the patient has fibrosis stage F2, F3 or F4 according to the Metavir scoring system.

96. A pharmaceutical oral formulation for use in improving cardiac function in an ALMS patient, said pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

97. The formulation for use of item 96, wherein the cardiac function is left ventricular function (LVF) and/or short-axis (plane) longitudinal relaxation time (SAX T1).

98. The formulation for use of item 97, wherein the LVF comprises left ventricular end-diastolic volume (LVEDV) and/or left ventricular end-systolic volume (LVESV).

99. The formulation for use of item 97 or 98, wherein the patient has a lower than normal LVF.

100. The formulation for use of item 99, wherein (i) the patient is a male and has a LVEDV of less than 106 mL and/or a LVESV of less than 26 mL; or (ii) the patient is a female and has a LVEDV of less than 86 mL and/or a LVESV of less than 22 mL.

101. A pharmaceutical oral formulation for use in improving kidney function in an ALMS patient suffering from kidney damage or injury, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

102. The formulation for use of item 101, wherein the patient has higher than normal levels of one or more biomarkers of kidney toxicity.

103. The formulation for use of item 102, wherein the one or more biomarkers of kidney injury are monocyte chemoattractant protein 1 (MCP-1), kidney injury molecule-1 (KIM-1), clusterin, cystatin C and osteopontin.
- 5 104. A pharmaceutical oral formulation for use in improving adipose tissue function in an ALMS patient, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
- 10 105. The formulation for use of item 104, wherein the adipose tissue function is perivascular adipose tissue function.
106. The formulation for use of any one of items 91 to 105, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 24 weeks.
- 15 107. The formulation for use of item 106, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 48 weeks.
108. The formulation for use of item 106, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 60 weeks.
- 20 109. The formulation for use of any one of items 59 to 108, wherein the daily dose is of about 700 mg to about 900 mg.
110. The formulation for use of item 109, wherein the daily dose is of about 800 mg.
111. The formulation for use of any one of items 59 to 108, wherein the daily dose is of about 1100 mg to about 1300 mg.
112. The formulation for use of item 111, wherein the daily dose is of about 1200 mg.
- 25 113. The formulation for use of any one of items 59 to 112, wherein the pharmaceutical oral formulation comprises sodium 2-(3-pentylphenyl)acetate.
114. The formulation for use of any one of items 59 to 113, wherein the pharmaceutical oral formulation is a capsule or a tablet.

115. The formulation for use of any one of items 59 to 114, wherein the subject has a body mass index (BMI) $\geq 25.0 \text{ kg/m}^2$.

116. The formulation for use of any one of items 59 to 115, wherein the subject is a male and has a waist circumference $\geq 94 \text{ cm}$, or the subject is a female and has a waist circumference $\geq 80 \text{ cm}$.

Other objects, advantages and features of the present disclosure will become more apparent upon reading of the following non-restrictive description of specific embodiments thereof, given by way of example only with reference to the accompanying drawings.

BRIEF DESCRIPTION OF DRAWINGS

In the appended drawings:

FIG. 1 depicts a flowchart of study design.

FIGs. 2A and 2B are histological images of adipocyte tissue in an ALMS subject before (**FIG. 2A**) and after (**FIG. 2B**) 24 weeks of treatment with sodium 2-(3-pentylphenyl)acetate. In **FIG. 2A**, asterisks (*) represent coalescence of adipocytes forming bigger vesicular vacuolation/steatosis (macrovesicular vacuolation).

FIGs. 3A and 3B are histological images of adipocyte tissue artery in an ALMS subject before (**FIG. 3A**) and after (**FIG. 3B**) 24 weeks of treatment with sodium 2-(3-pentylphenyl)acetate.

DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

The use of the terms "a" and "an" and "the" and similar referents in the context of describing the various aspects and embodiments disclosed herein (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context.

The terms "comprising", "having", "including", and "containing" are to be construed as open-ended terms (i.e., meaning "including, but not limited to") unless otherwise noted.

Recitation of ranges of values herein are merely intended to serve as a shorthand method of referring individually to each separate value falling within the range, unless otherwise indicated herein, and each separate value is incorporated into the specification as if it were individually recited herein. All subsets of values within the ranges are also incorporated into the specification as if they were individually recited herein.

Any and all combinations and subcombinations of the embodiments and features disclosed herein are encompassed by the present disclosure.

All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context.

The use of any and all examples, or exemplary language (e.g., "such as") provided herein, is intended merely to better illustrate the disclosure and does not pose a limitation on the scope of the disclosure unless otherwise claimed.

No language in the specification should be construed as indicating any non-claimed
5 element as essential to the practice of the various aspects and embodiments disclosed herein.

Herein, the term "about" has its ordinary meaning. The term "about" is used to indicate that a value includes an inherent variation of error for the device or the method being employed to determine the value, or encompass values close to the recited values, for example within 10% of the recited values (or range of values).

10 In the study described herein, sustained administration of 800 mg of sodium 2-(3-pentylphenyl)acetate improves the pathological features of several organs/tissues, as well as certain metabolic parameters, in subjects suffering from ALMS, and that significant interruption of treatment within the treatment period may lead to worsening of symptoms.

Accordingly, in a first aspect, the present disclosure provides a method for improving at
15 least one of liver histology, heart histology, kidney histology adipocyte histology and a metabolic parameter (e.g., glycemic control) in a subject suffering from ALMS, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered
20 at a daily dose of about 500 mg to about 1500 mg for a treatment period of more than 48 weeks, and wherein the administration is not interrupted for 15 days or more during said treatment period.

The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for improving at least one of liver histology, heart histology, kidney histology
25 adipocyte histology and a metabolic parameter (e.g., glycemic control) in a subject suffering from ALMS, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg for a treatment period of more than 48 weeks, and wherein there is no treatment interruption of 15 days or more during said treatment period.

30 The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for the manufacture of a medicament for improving at least one of liver histology, heart histology, kidney histology adipocyte histology and a metabolic parameter (e.g., glycemic control) in a subject suffering from ALMS, wherein said medicament is for administration
35 of 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof at a daily dose of about 500 mg to about 1500 mg for a treatment period of more than 48 weeks, and wherein there is no treatment interruption of 15 days or more during said treatment period.

The present disclosure also provides a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for use in improving at least one of liver histology, heart histology, kidney histology, adipose tissue histology and a metabolic parameter (e.g., glycemic control) in a subject suffering from ALMS, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg for a treatment period of more than 48 weeks, and wherein there is no treatment interruption of 15 days or more during said treatment period.

The present disclosure also provides a method for improving glycemic control in an ALMS patient with diabetes, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for improving glycemic control in an ALMS patient with diabetes, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for the manufacture of a medicament for improving glycemic control in an ALMS patient with diabetes, wherein said medicament is for administration of 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for use in improving glycemic control in an ALMS patient with diabetes, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides a method for improving liver function in an ALMS patient with liver disease, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for improving liver function in an ALMS patient with liver fibrosis (e.g., with

stage F2, F3 or F4 fibrosis according to the Metavir scoring system), wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for the manufacture of a medicament for improving liver function in an ALMS patient with liver fibrosis (e.g., with stage F2, F3 or F4 fibrosis according to the Metavir scoring system), wherein said medicament is for administration of 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for use in improving liver function in an ALMS patient with liver fibrosis (e.g., with stage F2, F3 or F4 fibrosis according to the Metavir scoring system), wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

In an embodiment, the liver disease comprises liver fibrosis, e.g., stage F2, F3 or F4 fibrosis according to the Metavir scoring system.

The present disclosure also provides a method for improving left ventricular function in an ALMS patient, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for improving left ventricular function in an ALMS patient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for the manufacture of a medicament for improving left ventricular function in an ALMS patient, wherein said medicament is for administration of 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for use in improving left ventricular function in an ALMS patient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

In an embodiment, the LVF comprises left ventricular end-diastolic volume (LVEDV) and/or left ventricular end-systolic volume (LVESV). In an embodiment, the ALMS patient has a left ventricular function that is lower than the normal range. The normal LVEDV range is 106-214 mL for males and 86-178 mL for females, and the normal LVESV range is 26-82 mL for males and 22-66 mL for females. In an embodiment, the patient is a male and has a LVEDV of less than 106 mL and/or a LVESV of less than 26 mL. In another embodiment, the patient is a female and has a LVEDV of less than 86 mL and/or a LVESV of less than 22 mL.

The present disclosure also provides a method for improving short-axis (plane) longitudinal relaxation time (SAX T1) in an ALMS patient, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for improving short-axis (plane) longitudinal relaxation time (SAX T1) in an ALMS patient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for the manufacture of a medicament for improving short-axis (plane) longitudinal relaxation time (SAX T1) in an ALMS patient, wherein said medicament is for administration of 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for use in improving short-axis (plane) longitudinal relaxation time (SAX T1) in an ALMS patient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides a method for improving kidney function in an ALMS patient suffering from kidney damage or injury, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically

acceptable excipient for improving kidney function in an ALMS patient suffering from kidney damage or injury, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

5 The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for the manufacture of a medicament for improving kidney function in an ALMS patient suffering from kidney damage or injury, wherein said medicament is for administration of 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof at a daily dose of about 500 mg to about 1500 mg.

10 The present disclosure also provides a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for use in improving kidney function in an ALMS patient suffering from kidney damage or injury, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.


15 The present disclosure also provides a method for improving adipose tissue function (e.g., perivascular adipose tissue function) in an ALMS patient, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

20 The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for improving adipose tissue function (e.g., perivascular adipose tissue function) in an ALMS patient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

25 The present disclosure also provides the use of a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for the manufacture of a medicament for improving adipose tissue function (e.g., perivascular adipose tissue function) in an ALMS patient, wherein said medicament is for administration of 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof at a daily dose of about 500 mg to about 1500 mg.


30 The present disclosure also provides a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient for use in improving adipose tissue function (e.g., perivascular adipose tissue function) in an ALMS patient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg.

2-(3-pentylphenyl)acetate has the following structure (shown as the corresponding acid):



The salt of 2-(3-pentylphenyl)acetate is a pharmaceutically acceptable salt. The term "pharmaceutically acceptable salt" refers to salts of 2-(3-pentylphenyl)acetate that are pharmacologically acceptable and substantially non-toxic to the subject to which they are administered. More specifically, these salts retain the biological effectiveness and properties of 2-(3-pentylphenyl)acetate and are formed from suitable non-toxic organic or inorganic acids or bases.

In an embodiment, the salt is a base salt formed with an inorganic or organic base. Such salts include alkali metal salts such as sodium, lithium, and potassium salts; alkaline earth metal salts such as calcium and magnesium salts; metal salts such as aluminum salts, iron salts, zinc salts, copper salts, nickel salts and a cobalt salts; inorganic amine salts such as ammonium or substituted ammonium salts, such as trimethylammonium salts; and salts with organic bases (for example, organic amines) such as chlorprocaine salts, dibenzylamine salts, dicyclohexylamine salts, diethanolamine salts, ethylamine salts (including diethylamine salts and triethylamine salts), ethylenediamine salts, glucosamine salts, guanidine salts, methylamine salts (including dimethylamine salts and trimethylamine salts), morpholine salts, morpholine salts, N,N'-dibenzylethylenediamine salts, N-benzyl-phenethylamine salts, N-methylglucamine salts, phenylglycine alkyl ester salts, piperazine salts, piperidine salts, procaine salts, t-butyl amines salts, tetramethylammonium salts, t-octylamine salts, tris-(2-hydroxyethyl)amine salts, and tris(hydroxymethyl)aminomethane salts. In an embodiment, the pharmaceutically acceptable base salt of 2-(3-pentylphenyl)acetate is a metal salt, preferably a sodium salt. Thus, in an embodiment, the pharmaceutical oral formulation comprises sodium 2-(3-pentylphenyl)acetate, also referred to as 3-pentylbenzeneacetic acid sodium salt, which has the following structure:



In an embodiment, the method, formulation or use is for at least improving liver histology. In an embodiment, the method, formulation or use is for at least improving heart histology. In an embodiment, the method, formulation or use is for at least improving kidney histology. In an embodiment, the method, formulation or use is for at least improving adipose tissue histology. In an embodiment, the method, formulation or use is for at least improving a metabolic parameter (e.g., glycemic control). In an embodiment, the method, formulation or use is for improving at least two features among liver histology, heart histology, kidney histology, adipose tissue histology (e.g., perivascular adipose tissue histology) and a metabolic parameter (e.g., glycemic control). In an embodiment, the method, formulation or use is for improving at least three features among liver histology, heart histology, kidney histology, adipose tissue histology and a metabolic

parameter (e.g., glycemic control). In an embodiment, the method, formulation or use is for improving at least four features among liver histology, heart histology, kidney histology, adipose tissue histology and a metabolic parameter (e.g., glycemic control). In an embodiment, the method, formulation or use is for improving liver histology, heart histology, kidney histology, adipose tissue histology and a metabolic parameter (e.g., glycemic control).

The terms “improving liver histology”, “improving heart histology”, “improving kidney histology”, and “improving adipose tissue histology” as used herein means that the method, formulation or use corrects or slows the progression of one or more pathological features associated with ALMS that was present in the recited organ or tissue from the patient prior to the treatment. The improvement may be determined by comparing the extent or severity of the one or more pathological features prior to and after the treatment period using suitable tests or assays. Improvement may also mean that the extent or severity of the one or more histopathological features has not worsened (i.e. is stable) after the treatment period or has worsened at a slower pace after the treatment period relative to an untreated patient (i.e. the progression of the pathological feature is slowed by the treatment).

Pathological features associated with ALMS include alterations of the normal structure or architecture of the organ or tissue that generally interfere with normal organ or tissue function, such as the presence of damages or injuries in the organ or tissue, the presence of scar tissue, and/or the presence of abnormal cells in the organ or tissue.

One of the pathological features associated with ALMS in the liver is increased liver stiffness. Thus, in embodiments, improving liver histology comprises reducing liver stiffness, or slowing the progression of liver stiffness. Liver stiffness may be determined using well-known methods and assays, including transient elastography (e.g., using FibroScan®). In an embodiment, the liver stiffness is reduced by at least 2 kPa relative to prior to the administration, as measured by transient elastography. In another embodiment, the liver stiffness is reduced by at least 2.1, 2.2, 2.25, 2.3, 2.35, 2.4, 2.45 or 2.5 kPa relative to prior to the administration, as measured by transient elastography. The extent or severity of liver stiffness may also be assessed using suitable scoring systems, such as the Metavir scoring system. The METAVIR scoring system is used to assess the extent of inflammation and fibrosis by histopathological evaluation in a liver biopsy of patients, and includes the following grades and stages:

Activity grade: A0 = no activity; A1 = mild activity; A2: moderate activity; A3: severe activity

Fibrosis stage: F0 = no fibrosis; F1 = portal fibrosis without septa; F2 = portal fibrosis with few septa; F3 = numerous septa without cirrhosis; F4 = cirrhosis.

In an embodiment, improving liver histology comprises reducing the Metavir score by at least one grade or stage, e.g., reduction in liver fibrosis by at least one grade. In another embodiment, improving liver histology comprises reducing the Metavir score by at least two

grades or stages, e.g., reduction in liver fibrosis by at least two grades. In another embodiment, improving liver histology comprises reducing the Metavir score by three grades or stages, e.g., reduction in liver fibrosis by three grades.

One of the histopathological features associated with ALMS in the heart is reduced left ventricular function (LVF). Thus, in embodiments, improving heart histology comprises increasing left ventricular function (LVF), or slowing the progression of reduction of LVF. LVF may be determined using well-known methods and assays, including cardiac Magnetic Resonance Imaging (MRI). In an embodiment, increasing LVF comprises increasing left ventricular end-diastolic volume (LVEDV) and/or left ventricular end-systolic volume (LVESV). In an embodiment, increasing LVF comprises increasing left ventricular end-diastolic volume (LVEDV). In an embodiment, the method, formulation or use increases LVEDV by at least 6 ml relative to prior to the administration, as measured by cardiac MRI. In another embodiment, the method, formulation or use increases LVEDV by at least 6.5, 7, 7.5 or 8 ml relative to prior to the administration, as measured by cardiac MRI.

Another histopathological feature associated with ALMS in the heart is short-axis (plane) longitudinal relaxation time (SAX T1). Thus, in an embodiment, improving heart histology comprises reducing SAX T1, such as Basal SAX T1 and/or Mid SAX T1. SAX T1 may be determined using well-known methods and assays, including cardiac MRI. In an embodiment, the method, formulation or use is for reducing Basal SAX T1 by at least 40 ms relative to prior to the administration, as measured by cardiac MRI. In another embodiment, the method, formulation or use is for reducing Basal SAX T1 by at least 45, 50, 55 or 60 ms relative to prior to the administration, as measured by cardiac MRI. In an embodiment, the method, formulation or use is for reducing Mid SAX T1 by at least 25 ms relative to prior to the administration, as measured by cardiac MRI. In another embodiment, the method, formulation or use is for reducing Mid SAX T1 by at least 30, 35, 40 or 45 ms relative to prior to the administration, as measured by cardiac MRI.

One of the histopathological features associated with ALMS in the kidney is the presence of kidney damage or injury. Thus, in an embodiment, improving kidney histology comprises inhibiting or slowing the progression of kidney damage or injury. Kidney damage or injury may be determined using well-known methods and assays, such as by measuring the Albumin-to-creatinine ratio (ACR) or the levels of one or more biomarkers of kidney injury, such as monocyte chemoattractant protein 1 (MCP-1), kidney injury molecule-1 (KIM-1), clusterin, cystatin C and osteopontin. In an embodiment, the method, formulation or use is for inhibiting or slowing the increase of the ACR in the subject. In another embodiment, the method, formulation or use is for inhibiting or slowing the increase of the ACR in the subject. In another embodiment, the method, formulation or use is for reducing the levels of one or more biomarkers of kidney injury. In an embodiment, the levels of one or more of MCP-1, KIM-1, clusterin, cystatin C and osteopontin is

reduced. In a further embodiment, the levels of MCP-1, KIM-1, clusterin, cystatin C and osteopontin is reduced. In an embodiment, the levels of the one or more biomarkers is reduced by at least 10% relative to prior to the treatment. In another embodiment, the levels of the one or more biomarkers is reduced by at least 15%, 20%, 25% or 30% relative to prior to the treatment.

5 One of the histopathological features associated with ALMS in adipose tissue is the hypertrophy and coalescence of adipocytes, forming giant vesicular vacuolation/steatosis. Thus, in an embodiment, improving adipose tissue histology comprises reducing average adipocyte area. In an embodiment, the method, formulation or use is for reducing average adipocyte area by at least 10% relative to prior to the administration. In another embodiment, the method,
10 formulation or use is for reducing average adipocyte area by at least 15% or 20% relative to prior to the administration.

Adipose tissue artery (perivascular adipose tissue) in ALMS patients is characterized by signs of dystrophy, homogenized blurred cytoplasm in smooth muscle cells, and nuclei with irregular shape. Thus, in an embodiment, improving adipose tissue histology comprises restoring
15 normal adipose tissue artery.

ALMS is also associated with several metabolic abnormalities. Insulin resistance, hyperinsulinemia, and impaired glucose tolerance often present in very early childhood. Type 2 diabetes (T2DM) develops in childhood, adolescence, or adulthood, with a mean age of onset at 16 years. Children with ALMS also often have high lipid levels at an early age. Thus, in an
20 embodiment, improving a metabolic parameter comprises improving glycemic control. Glycemic control may be assessed using well-known methods and assays. In a further embodiment, improving glycemic control comprises reducing glycated hemoglobin (HbA1c). In an embodiment, the method, formulation or use is for reducing HbA1c by at least 0.5% or 1% (absolute).

In another embodiment, improving glycemic control comprises increasing the homeostasis Model Assessment for Steady State Beta-Cell Function Based on C-Peptide and Fasting Plasma Glucose (HOMA-B [C-Peptide/FPG]). In an embodiment, the method, formulation
25 or use is for increasing HOMA-B [C-Peptide/FPG] by at least 20 relative to prior to the administration. In another embodiment, the method, formulation or use is for increasing HOMA-B [C-Peptide/FPG] by at least 25, 30 or 35 relative to prior to the administration.

30 In an embodiment, the ALMS patient is overweight, i.e. has a body mass index (BMI) $\geq 25.0 \text{ kg/m}^2$. In another embodiment, the ALMS patient is obese, i.e. has a BMI $\geq 30.0 \text{ kg/m}^2$.

In an embodiment, the ALMS patient is a male and has a waist circumference $\geq 94 \text{ cm}$. In another embodiment, the ALMS patient is a female and has a waist circumference $\geq 80 \text{ cm}$.

In an embodiment, the ALMS patient suffers from diabetes. In a further embodiment, the
35 ALMS patient suffers from type 1 diabetes. In another embodiment, the ALMS patient suffers from type 2 diabetes.

In an embodiment, the ALMS patient has a Metavir Score (determined based on liver FibroScan results) of F2 or worse. In an embodiment, the ALMS patient has a Metavir Score (based on liver FibroScan results) of F3 or worse. In an embodiment, the ALMS patient has a Metavir Score (based on liver FibroScan results) of F4.

5 In an embodiment, the ALMS patient is a pediatric patient (17 years old or less). In another embodiment, the ALMS patient is an adult patient. In another embodiment, the ALMS patient is 18 to 52 years old, e.g. 20 to 35 years old.

10 In an embodiment, the 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered or for administration at a daily dose of about 500 mg to about 1500 mg, about 600 mg to about 1400 mg, about 700 mg to about 1300 mg, about 600 mg to about 1000 mg, about 700 mg to about 900 mg, about 750 mg to about 850 mg, about 775 mg to about 825 mg, about 900 mg to about 1500 mg, about 1000 mg to about 1400 mg, about 1100 mg to about 1300 mg, about 1150 mg to about 1250 mg, or about 11750 mg to about 1225 mg. In a further embodiment, the 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered or for
15 administration at a daily dose of about 800 mg, about 900 mg, about 1000 mg, about 1100 mg, or about 1200 mg. The daily dose may be administered using a single dosage form or using a plurality of dosage forms (e.g., tablets, capsules). If the daily dose is administered using a plurality of dosage forms (e.g., 2, 3 or 4 dosage forms), the plurality of dosage forms may be taken at the same time or at different times during the day. In an embodiment, the plurality of dosage forms is
20 taken at the same time.

In an embodiment, there is no treatment interruption of 20 days (e.g., consecutive days) or more during said treatment period. In an embodiment, there is no treatment interruption of 25 days (e.g., consecutive days) or more during said treatment period. In an embodiment, there is no treatment interruption of 30 days (e.g., consecutive days) or more during said treatment period.
25 The term "treatment interruption" as used herein means a subject that does not take the above-noted daily dosage of 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof for the specified number of days during the treatment period.

In an embodiment, the treatment period is at least 54 weeks. In another embodiment, the treatment period is at least 60 weeks.

30 The pharmaceutical oral formulation may be prepared by using standard methods known in the art by mixing the 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof having the desired degree of purity with one or more pharmaceutically acceptable excipients (see Remington: *The Science and Practice of Pharmacy*, by Loyd V Allen, Jr., 2012, 22nd edition, Pharmaceutical Press; *Handbook of Pharmaceutical Excipients*, by Rowe *et al.*, 2012, 7th edition,
35 Pharmaceutical Press).

"Pharmaceutically acceptable excipient" as used herein refers to any excipient that does not interfere with effectiveness of the biological activity of the 2-(3-pentylphenyl)acetate or

pharmaceutically salt thereof and that is not toxic to the subject, *i.e.*, is a type of excipient and/or is for use in an amount which is not toxic to the subject. Excipients are well known in the art, and the present pharmaceutical oral formulation is not limited in these respects. In certain embodiments, the pharmaceutical oral formulation includes excipients, including for example and without limitation, one or more binders (binding agents), thickening agents, surfactants, diluents, release-delaying agents, colorants, flavoring agents, fillers, disintegrants/dissolution promoting agents, lubricants, plasticizers, silica flow conditioners, glidants, anti-caking agents, anti-tacking agents, stabilizing agents, anti-static agents, swelling agents and any combinations thereof. As those of skill would recognize, a single excipient can fulfill more than two functions at once, *e.g.*, can act as both a binding agent and a thickening agent. As those of skill will also recognize, these terms are not necessarily mutually exclusive.

Useful diluents, *e.g.*, fillers, include, for example and without limitation, dicalcium phosphate, calcium diphosphate, calcium carbonate, calcium sulfate, lactose, cellulose, kaolin, sodium chloride, starches, powdered sugar, colloidal silicon dioxide, titanium oxide, alumina, talc, colloidal silica, microcrystalline cellulose, silicified micro crystalline cellulose and combinations thereof. Fillers that can add bulk to tablets with minimal drug dosage to produce tablets of adequate size and weight include croscarmellose sodium NF/EP (*e.g.*, Ac-Di-Sol); anhydrous lactose NF/EP (*e.g.*, Pharmatose™ DCL 21); and/or povidone USP/EP.

Binder materials include, for example and without limitation, starches (including corn starch and pregelatinized starch), gelatin, sugars (including sucrose, glucose, dextrose and lactose), polyethylene glycol, povidone, waxes, and natural and synthetic gums, *e.g.*, acacia sodium alginate, polyvinylpyrrolidone, cellulosic polymers (*e.g.*, hydroxypropyl cellulose, hydroxypropyl methylcellulose, methyl cellulose, hydroxyethyl cellulose, carboxymethylcellulose, colloidal silicon dioxide NF/EP (*e.g.*, Cab-O-Sil™ M5P), Silicified Microcrystalline Cellulose (SMCC), *e.g.*, Silicified microcrystalline cellulose NF/EP (*e.g.*, Prosolv™ SMCC 90), and silicon dioxide, mixtures thereof, and the like), veegum, and combinations thereof.

Useful lubricants include, for example, canola oil, glyceryl palmitostearate, hydrogenated vegetable oil (type I), magnesium oxide, magnesium stearate, mineral oil, poloxamer, polyethylene glycol, sodium lauryl sulfate, sodium stearate fumarate, stearic acid, talc and, zinc stearate, glyceryl behapate, magnesium lauryl sulfate, boric acid, sodium benzoate, sodium acetate, sodium benzoate/sodium acetate (in combination), DL-leucine, calcium stearate, sodium stearyl fumarate, mixtures thereof, and the like.

Bulking agents include, for example: microcrystalline cellulose, for example, AVICEL® (FMC Corp.) or EMCOCEL® (Mendell Inc.), which also has binder properties; dicalcium phosphate, for example, EMCOMPRESS® (Mendell Inc.); calcium sulfate, for example, COMPACTROL® (Mendell Inc.); and starches, for example, Starch 1500; and polyethylene glycols (CARBOWAX®).

Disintegrating or dissolution promoting agents include: starches, clays, celluloses, alginates, gums, crosslinked polymers, colloidal silicon dioxide, osmogens, mixtures thereof, and the like, such as crosslinked sodium carboxymethyl cellulose (AC-DI-SOL[®]), sodium croscarmellose, sodium starch glycolate (EXPLOTAB[®], PRIMO JEL[®]) crosslinked
5 polyvinylpyrrolidone (PLASONE-XL[®]), sodium chloride, sucrose, lactose and mannitol.

Antiadherents and glidants employable in the core and/or a coating of the solid oral dosage form may include talc, starches (e.g., cornstarch), celluloses, silicon dioxide, sodium lauryl sulfate, colloidal silica dioxide, and metallic stearates, among others.

10 Examples of silica flow conditioners include colloidal silicon dioxide, magnesium aluminum silicate and guar gum.

Suitable surfactants include pharmaceutically acceptable non-ionic, ionic and anionic surfactants. An example of a surfactant is sodium lauryl sulfate. If desired, the pharmaceutical composition to be administered may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, pH-buffering agents and the like, for example, sodium
15 acetate, sorbitan monolaurate, triethanolamine sodium acetate, triethanolamine oleate, etc. If desired, flavoring, coloring and/or sweetening agents may be added as well.

Examples of stabilizing agents include acacia, albumin, polyvinyl alcohol, alginic acid, bentonite, dicalcium phosphate, carboxymethylcellulose, hydroxypropylcellulose, colloidal silicon dioxide, cyclodextrins, glyceryl monostearate, hydroxypropyl methylcellulose, magnesium
20 trisilicate, magnesium aluminum silicate, propylene glycol, propylene glycol alginate, sodium alginate, carnauba wax, xanthan gum, starch, stearate(s), stearic acid, stearic monoglyceride and stearyl alcohol.

Examples of thickening agents include talc USP/EP, a natural gum, such as guar gum or gum arabic, or a cellulose derivative such as microcrystalline cellulose NF/EP (e.g., Avicel[™]
25 PH 102), methylcellulose, ethylcellulose or hydroxyethylcellulose. A useful thickening agent is hydroxypropyl methylcellulose, an adjuvant which is available in various viscosity grades.

Examples of plasticizers include: acetylated monoglycerides; these can be used as food additives; Alkyl citrates, used in food packagings, medical products, cosmetics and children toys; Triethyl citrate (TEC); Acetyl triethyl citrate (ATEC), higher boiling point and lower volatility than
30 TEC; Tributyl citrate (TBC); Acetyl tributyl citrate (ATBC), compatible with PVC and vinyl chloride copolymers; Trioctyl citrate (TOC), also used for gums and controlled release medicines; Acetyl trioctyl citrate (ATOC), also used for printing ink; Trihexyl citrate (THC), compatible with PVC, also used for controlled release medicines; Acetyl trihexyl citrate (ATHC), compatible with PVC; Butyryl trihexyl citrate (BTHC, trihexyl o-butyryl citrate), compatible with PVC; Trimethyl citrate (TMC),
35 compatible with PVC; alkyl sulphonic acid phenyl ester, polyethylene glycol (PEG) or any combination thereof. Optionally, the plasticizer can comprise triethyl citrate NF/EP.

Examples of permeation enhancers include: sulphoxides (such as dimethylsulphoxide, DMSO), azones (e.g. laurocapram), pyrrolidones (for example 2-pyrrolidone, 2P), alcohols and alkanols (ethanol, or decanol), glycols (for example propylene glycol and polyethylene glycol), surfactants and terpenes.

Formulations suitable for oral administration include capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as liquids, solids, granules or gelatin. Tablet forms can include one or more of lactose, sucrose, mannitol, sorbitol, calcium phosphates, corn starch, potato starch, microcrystalline cellulose, gelatin, colloidal silicon dioxide, talc, magnesium stearate, stearic acid, and other excipients, colorants, fillers, binders, diluents, buffering agents, moistening agents, preservatives, flavoring agents, dyes, disintegrating agents, and pharmaceutically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, e.g., sucrose, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, carriers known in the art.

In an embodiment, the pharmaceutical oral formulation is a capsule or a tablet. In an embodiment, the pharmaceutical oral formulation is a capsule. In another embodiment, the pharmaceutical oral formulation is a tablet.

EXAMPLES

The present disclosure is illustrated in further details by the following non-limiting examples.

Example 1: Details of clinical study

Methods

The study was a Phase 2, single-centre, single-arm, open-label study of sodium 2-(3-pentylphenyl)acetate administered at a total daily oral dose of 800 mg for up to 72 weeks in subjects with ALMS was undertaken. The initial duration of the study was 24 weeks, and subjects were offered to enrol into an extension phase of 36 or 48 weeks. The schedule of study procedures for the enrolment, intervention, and assessments for participants is outlined in **FIG. 1**.

Sodium 2-(3-pentylphenyl)acetate was formulated in soft gelatine capsules containing 200 mg of Sodium 2-(3-pentylphenyl)acetate (amorphous powder) per capsule, polyethylene glycol 400, National Formulary (NF), hydrochloric acid (for pH adjustment), and water.

Study population and eligibility criteria

A total of 15 subjects participated in the study. Three subjects did not meet eligibility criteria and were not enrolled into the study (i.e., screen failures). Twelve (12) subjects met the eligibility criteria and received at least 1 dose of 800 mg sodium 2-(3-pentylphenyl)acetate, with all 12 subjects completing the initial 24-week treatment period as planned. A 36-week EP was

added to the study protocol (Table 1). Ten (10) of the 12 subjects who completed the initial 24-week study drug treatment period continued in the EP, with 6 subjects having a break in treatment until the amendment was implemented before continuing treatment in the EP and 4 subjects continuing in the EP without any break in treatment. Two subjects (826-001-002 and 826-001-014) completed the study after the initial 24-week study drug treatment period.

Table 1: Listing of Subjects Who Continued Study Drug Treatment in the Extension Period

Subject ID	Break in Treatment (Yes or No)	Duration of Treatment Break
826-001-001	Yes	204 days
826-001-003	Yes	32 days
826-001-004	Yes	30 days
826-001-005	Yes	39 days
826-001-006	No	NA
826-001-007	Yes	32 days
826-001-009	No	NA
826-001-012	No	NA
826-001-013	Yes	30 days
826-001-015	No	NA

ID = identification number; NA = not applicable.

Of the 10 subjects continuing study drug treatment in the EP, all but 1 subject completed the study as planned.

The mean age (range) of the subject population was 26.1 years (17-52 years), with most subjects being male and White (66.7%), and none of the subjects were Hispanic or Latino (Table 2). Half of the subjects were obese (body mass index [BMI] ≥ 30.0 kg/m²), and all but 1 subject was at least overweight (BMI ≥ 25.0 kg/m²). In addition, most subjects had a waist circumference at increased risk of health problems (males ≥ 94 cm and females ≥ 80 cm).

Table 2: Baseline Demographic Characteristics

Subject ID	Age	Gender	Ethnicity	Race	Weight (kg)	Waist Circumference (cm)	Height (cm)	BMI (kg/m ²)
826-001-001	20	Male	NHL	White	69.6	94.0	165.0	25.56
826-001-002	31	Male	NHL	White	82.1	97.0	159.0	32.47
826-001-003	24	Female	NHL	White	83.4	99.0	164.0	31.01
826-001-004	25	Female	NHL	White	58.4	87.5	152.8	25.01
826-001-005	22	Male	NHL	White	72.6	87.5	166.0	26.35
826-001-006	20	Female	NHL	Asian	104.0	125.0	151.0	45.61

Subject ID	Age	Gender	Ethnicity	Race	Weight (kg)	Waist Circumference (cm)	Height (cm)	BMI (kg/m ²)
826-001-007	20	Male	NHL	Asian	86.1	99.0	166.0	31.25
826-001-009	24	Male	NHL	White	87.9	105.5	170.0	30.42
826-001-012	52	Male	NHL	White	85.8	105.0	150.0	38.13
826-001-013	17	Male	NHL	Asian	69.9	85.0	165.0	25.67
826-001-014	23	Male	NHL	Asian	62.9	86.0	150.0	27.96
826-001-015	35	Female	NHL	White	53.1	82.0	146.5	24.74

BMI = body mass index; ID = identification number; NHL = not Hispanic/Latino.

The median duration (range) of ALMS was 13.2 years (3-22 years), and most subjects had type 2 diabetes (T2D; 83.3%), significant liver fibrosis (Metavir score ≥ 2 ; 72.7%), and kidney disease (75.0%; Table 3). Of note, Subject 826-001-003 had both type 1 diabetes (T1D) and T2D; Subjects 826-001-007 and 826-001-015 had possible cirrhosis (based on FibroScan[®] results); and Subject 826-001-012 had possible heart failure.

Table 3: Baseline Characteristics

Subject ID	ALMS Duration ^a (months)	Diabetes Status	Metavir Score Based on Liver FibroScan [®] Results ^b	NT-pro-BNP ^c (ng/L)	ACR ^d (mg/mmol)
826-001-001	169.7	Type 2	F3	34	6.3
826-001-002	159.3	Type 2	F2	< 10	17.6
826-001-003	183.3	Type 1/2	F0/1	59	13.7
826-001-004	106.7	Type 2	F2	68	17.7
826-001-005	171.8	None	F0/1	8	0.7
826-001-006	38.5	None	F2	59	4.4
826-001-007	52.2	Type 2	F4	34	44.5
826-001-009	156.8	Type 2	F0/1	< 10	1.7
826-001-012	59.2	Type 2	F3	279	6.9
826-001-013	65.7	Type 2	F3	< 10	41.5
826-001-014	266.8	Type 2	---	51	18.6
826-001-015	183.3	Type 2	F4	25	1.1

--- = no data available; ACR = albumin/creatinine ratio; ALMS = Alström syndrome; ICF = informed consent form; ID = identification number; NT-pro-BNP = N-terminal pro-brain natriuretic peptide.

^a ALMS duration was measured from the diagnosis date to the ICF date.

^b The Metavir scoring system is a tool used to evaluate the severity of liver fibrosis using transient elastography (FibroScan[®]). Metavir score F0-F1: absence or mild fibrosis (2.5-7.0 kPa on FibroScan[®]); Metavir score F2: significant fibrosis (≥ 7.1 to < 9.5 kPa on FibroScan[®]); Metavir

score F3: severe fibrosis (≥ 9.5 to < 12.5 kPa on FibroScan®; and Metavir score F4: cirrhosis (≥ 12.5 kPa on FibroScan®).

^c Normal range: < 125 ng/L in subjects 0-74 years of age.

^d ACR < 3.39 mg/mmol = normal; ACR 3.39 to 33.9 mg/mmol = early kidney disease (microalbuminuria); and ACR > 33.9 mg/mmol = more advanced kidney disease (macroalbuminuria).

Example 2: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on liver

There is phenotypic variation in the slowly progressive hepatic dysfunction in Alström syndrome, which begins with clinically silent elevation of transaminases, and steatosis. The initial presentation is usually steatosis and hepatosplenomegaly followed by fibrotic and inflammatory processes with lymphocytic infiltration in the portal and parenchymal areas. In the final course of hepatic disease, there is significant fibrosis, cirrhosis, and portal hypertension (Marshall *et al.*, *Curr Genomics*. 2011 May; 12(3): 225-235).

A) Liver stiffness

The effect of sodium 2-(3-pentylphenyl)acetate on liver histology in ALMS patients was first assessed by measuring liver stiffness. Liver stiffness is a physical parameter that reflects the health of the liver and is commonly used to diagnose liver diseases. Increased liver stiffness may be associated with hepatic dysfunction.

Statistically significant decreases in liver stiffness from baseline, as measured by transient elastography via FibroScan®, were seen after 60 weeks of treatment with sodium 2-(3-pentylphenyl)acetate (2.59 kPa; $p = 0.0207$; Table 4).

Table 4: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on the Change from Baseline in Liver Stiffness Using Transient Elastography (FibroScan®): Change from Baseline Transient Elastography (kPa)

Statistics	Change from Baseline Transient Elastography (kPa)				
	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)
N	11	11	10	10	9
Mean (SD)	-1.19 (2.160)	-1.01 (2.308)	-1.41 (2.585)	-1.49 (2.335)	-2.59 (2.703)
Median	-1.50	-0.70	-1.75	-1.45	-2.30
PT P-value	0.0974	0.1777	0.1187	0.0744	0.0207
PT 95% CI	-2.64, 0.26	-2.56, 0.54	-3.26, 0.44	-3.16, 0.18	-4.67, -0.51
SW P-value	0.5017	0.4882	0.4217	0.9457	0.7706
WS P-value	0.1055	0.1416	0.0840	0.0977	0.0195

CI = confidence interval; EP = Extension Period; PT = paired t-test; SD = standard deviation; SW = Shapiro-Wilk test; WS = Wilcoxon signed-rank test.

Liver stiffness was variable at baseline, ranging from 5.1 to 21.1 kPa (Table 5), with the lowest baseline liver stiffness occurring in a non-diabetic subject with no medical history of liver disease (826-001-005) and the highest baseline liver stiffness occurring in a T2D subject with an ongoing medical history of abnormal hepatic function (826-001-007). Liver stiffness decreased from baseline in the majority of subjects (8/11, 72.3%) after study drug treatment with 800 mg sodium 2-(3-pentylphenyl)acetate. Decreases in liver stiffness from baseline ranged from 0.6 to 8.0 kPa. Of note, a total of 4 subjects (826-001-001, 826-001-004, 826-001-012, and 826-001-015) had at least a 1-grade reduction in liver fibrosis, as assessed by the Metavir scoring system, after study drug treatment. This included 1 subject (826-001-015) whose Metavir score decreased from F4 (baseline) to F0/1 (Week 60). The largest increase in liver stiffness from baseline occurred in Subject 826-001-013 (1.8 kPa), who had a 30-day break in study drug treatment between Week 24 and the start of the EP.

Table 5: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on Liver Stiffness Using Transient Elastography (FibroScan®): Transient Elastography Score (kPa) and Metavir Score (F) – individual results

Subject ID	Transient Elastography Score (kPa) and Metavir Score (F) ^a					
	Baseline	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)
826-001-001 ^{b, c}	9.9 (F3)	7.1 (F2)	7.2 (F2)	6.6 (F0/1)	7.1 (F2)	7.8 (F2)
826-001-002 ^c	7.4 (F2)	6.1 (F0/1)	7.6 (F2)	---	---	---
826-001-003 ^{d, e}	6.1 (F0/1)	4.5 (F0/1)	5.9 (F0/1)	4.2 (F0/1)	4.1 (F0/1)	3.8 (F0/1)
826-001-004 ^f	8.1 (F2)	5.3 (F0/1)	5.2 (F0/1)	6.5 (F0/1)	4.7 (F0/1)	5.0 (F0/1)
826-001-005 ^{c, g, h}	5.1 (F0/1)	3.1 (F0/1)	4.6 (F0/1)	4.6 (F0/1)	5.1 (F0/1)	3.9 (F0/1)
826-001-006 ^{c, h}	8.8 (F2)	10.5 (F3)	8.1 (F2)	8.9 (F2)	7.5 (F2)	---
826-001-007 ^{c, d}	21.1 (F4)	19.6 (F4)	21.8 (F4)	18.6 (F4)	21.6 (F4)	17.1 (F4)
826-001-009 ^c	6.6 (F0/1)	7.8 (F2)	5.6 (F0/1)	5.8 (F0/1)	5.0 (F0/1)	6.0 (F0/1)
826-001-012	12.4 (F3)	12.2 (F3)	8.6 (F2)	10.2 (F3)	12.1 (F3)	8.6 (F2)
826-001-013 ^f	10.4 (F3)	12.0 (F3)	14.3 (F4)	14.7 (F4)	12.6 (F4)	12.2 (F3)
826-001-014 ^{c, e}	---	50.5 (F4)	48.9 (F4)	---	---	---
826-001-015 ^c	13.1 (F4)	7.7 (F2)	9.0 (F2)	7.4 (F2)	6.9 (F0/1)	5.1 (F0/1)

--- = no data available; EP = Extension Period; ID = identification number.

^a The Metavir scoring system is a tool used to evaluate the severity of liver fibrosis using transient elastography (FibroScan). Metavir score F0-F1: absence or mild fibrosis (2.5-7.0 kPa on FibroScan®); Metavir score F2: significant fibrosis (≥ 7.1 to < 9.5 kPa on

FibroScan®); Metavir score F3: severe fibrosis (≥ 9.5 to < 12.5 kPa on FibroScan®; and Metavir score F4: cirrhosis (≥ 12.5 kPa on FibroScan®).

^b 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

5 ^c Subject had ongoing medical history of liver disorder (e.g., hepatic steatosis, liver disorder, and/or hepatic function abnormal).

^d 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^e Insulin-dependent T2D subject.

10 ^f 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^g Non-diabetic.

^h 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

15 These results provide evidence that treatment with sodium 2-(3-pentylphenyl)acetate for a period of more than 48 weeks, and preferably for at least 60 weeks, leads to significant improvement of liver histology in ALMS patients, and that treatment interruption may lead to deterioration of liver histology.

20 B) NAFLD fibrosis score

The effect of sodium 2-(3-pentylphenyl)acetate on liver histology in ALMS patients was also assessed by measuring the Non-Alcoholic Fatty Liver Disease (NAFLD) Fibrosis Score. Increased NAFLD fibrosis score may be associated with hepatic dysfunction.

The results are depicted in Table 6.

25 Table 6: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on Non-Alcoholic Fatty Liver Disease Fibrosis Score

Statistics	Change from Baseline NAFLD Score with an FPG > 5.6 mmol/L ^a				
	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)
N	11	9	10	9	9
Mean (SD)	-0.35 (0.582)	0.16 (0.446)	-0.39 (0.683)	-0.34 (0.758)	-0.16 (0.684)
Median	-0.34	0.21	-0.69	-0.28	-0.14
PT P-value	0.0706	0.3067	0.1039	0.2155	0.5097
PT 95% CI	-0.75, 0.04	-0.18, 0.51	-0.88, 0.10	-0.92, 0.24	-0.68, 0.37
SW P-value	0.1911	0.8053	0.2399	0.0295	0.8666
WS P-value	0.0674	0.4961	0.1309	0.2031	0.7344

CI = confidence interval; EP = Extension Period; FPG = fasting plasma glucose; NAFLD = non-alcoholic fatty liver disease; NASH = non-alcoholic steatohepatitis; PT = paired t-test; SD = standard deviation; SW = Shapiro-Wilk test; WS = Wilcoxon signed-rank test.

- 5 ^a NAFLD Fibrosis Score: < -1.455 (low likelihood of NASH); -1.455 to 0.676 (indeterminate likelihood of NASH); > 0.676 (high likelihood of NASH).

Baseline NAFLD fibrosis scores ranged from -4.6 to 0.9 in subjects with either a baseline FPG > 5.6 mmol/L or > 6.0 mmol/L (Table 7), with most subjects (66.7%) having an NAFLD
10 fibrosis score associated with a low likelihood of non-alcoholic steatohepatitis. NAFLD fibrosis scores decreased or did not change from baseline in the majority of subjects (7/12, 58.3%) after study drug treatment with 800 mg sodium 2-(3-pentylphenyl)acetate. Of note, an increase in NAFLD fibrosis score from baseline occurred in Subjects 826-001-001 (0.7), who had a 204-day break in study drug treatment between Week 24 and the start of the EP.

15 **Table 7: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on Non-Alcoholic Fatty Liver Disease Fibrosis Score – individual results**

Subject ID	NAFLD Fibrosis Score in Subjects with an FPG > 5.6 mmol/L ^a					
	Baseline	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)
826-001-001 ^{b, c}	-2.2	-2.5	-1.5	-1.9	-1.9	-1.5
826-001-002 ^c	-1.8	-1.8	-1.9	---	---	---
826-001-003 ^{d, e}	-2.3	-3.9	-2.7	-3.1	-4.4	-3.7
826-001-004 ^f	-2.9	-3.1	-2.7	-3.8	-3.0	-2.9
826-001-005 ^{c, g, h}	-4.1	-3.9	-3.8	-3.8	-3.8	-4.2
826-001-006 ^{c, h}	-0.5	-1.4	-0.2	-1.6	-0.8	---
826-001-007 ^{c, d}	-0.5	-0.8	---	-1.2	-1.0	-1.1
826-001-009 ^c	-2.5	-3.3	-2.9	-3.8	-3.1	-2.9
826-001-012	0.9	0.6	---	0.2	0.5	0.2
826-001-013 ^f	-3.7	---	---	-3.6	---	-3.4
826-001-014 ^{c, e}	-1.0	-0.8	-1.0	---	---	---
826-001-015 ^c	-4.6	-4.3	-3.7	-3.8	-4.2	-3.8

--- = no data available; EP = Extension Period; FPG = fasting plasma glucose; ID = identification number; NAFLD = non-alcoholic fatty liver disease; NASH = non-alcoholic steatohepatitis.

- 20 ^a NAFLD Fibrosis Score: < -1.455 (low likelihood of NASH); -1.455 to 0.676 (indeterminate likelihood of NASH); > 0.676 (high likelihood of NASH).

^b 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

- ^c Subject had ongoing medical history of liver disorder (e.g., hepatic steatosis, liver disorder,
25 and/or hepatic function abnormal).

^d 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^e Insulin-dependent T2D subject.

^f 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^g Non-diabetic.

^h 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

C) Enhanced Liver Fibrosis Test

The effect of sodium 2-(3-pentylphenyl)acetate on liver histology in ALMS patients was also assessed using the Enhanced Liver Fibrosis (ELF™) blood test. The ELF™ Blood Test combines three serum biomarkers (Hyaluronic acid (HA), Procollagen III amino terminal peptide (PIIINP), and Tissue inhibitor of metalloproteinase 1 (TIMP-1)) which, when correlated, are able to identify a quantifiable level of liver fibrosis.

The results (changes from baseline) are depicted in Table 8.

Table 8: Effect of 800 mg PBI-4050 on the Change from Baseline in the Enhanced Liver Fibrosis Test

Statistics	Change from Baseline ELF Test				
	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)
N	12	12	10	9	8
Mean (SD)	0.02 (1.023)	-0.26 (0.933)	-0.24 (1.056)	-0.22 (1.086)	-0.26 (1.193)
Median	0.24	0.06	-0.02	-0.13	-0.03
PT P-value	0.9472	0.3564	0.4923	0.5565	0.5551
PT 95% CI	-0.63, 0.67	-0.85, 0.33	-0.99, 0.52	-1.06, 0.61	-1.26, 0.74
SW P-value	0.3329	0.5798	0.2689	0.6739	0.6982
WS P-value	0.7334	0.5186	0.6250	0.5703	0.7422

CI = confidence interval; ELF = Enhanced Liver Fibrosis; EP = Extension Period; PT = paired t-test; SD = standard deviation; SW = Shapiro-Wilk test; WS = Wilcoxon signed-rank test.

Baseline ELF test scores ranged from 7.11 and 11.65, with most subjects (66.7%) having moderate fibrosis (Table 9). ELF test scores decreased from baseline in half the subjects (6/12, 50.0%) after study drug treatment. Decreases in ELF test scores from baseline ranged from 0.1 to 1.75. Of note, the largest increases in ELF test scores from baseline occurred in Subjects 826-001-001 (1.36) and 826-001-004 (1.17), who had a break in study drug treatment

(204 and 30 days for Subjects 826-001-001 and 826-001-004, respectively) between Week 24 and the start of the EP.

Table 9: By-Subject Listing of the Enhanced Liver Fibrosis Test

Subject ID	ELF Test ^a					
	Baseline	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)
826-001-001 ^{b,c}	8.92	8.50	9.31	9.13	10.30	10.28
826-001-002 ^c	7.93	8.63	9.02	---	---	---
826-001-003 ^{d,e}	8.04	9.75	8.60	8.68	8.00	8.42
826-001-004 ^f	7.11	7.98	7.14	7.68	6.98	NA
826-001-005 ^{c,g,h}	9.30	7.93	7.26	8.19	7.45	7.16
826-001-006 ^{c,h}	8.70	7.33	7.31	6.80	6.95	---
826-001-007 ^{c,d}	11.65	10.05	10.39	9.92	NA	9.90
826-001-009 ^c	9.06	9.71	8.41	8.48	8.36	8.50
826-001-012	10.59	10.96	10.69	11.58	11.14	10.79
826-001-013 ^f	7.97	8.51	8.47	8.75	8.76	8.64
826-001-014 ^{c,e}	11.15	11.25	11.29	---	---	---
826-001-015 ^c	8.99	9.05	8.41	8.73	8.74	8.74

--- = no data available; ELF = Enhanced Liver Fibrosis; EP = Extension Period; ID = identification number; NA = not available.

^a ELF test score: None to mild fibrosis < 7.7; moderate fibrosis ≥ 7.7 to < 9.8; and severe fibrosis ≥ 9.8.

^b 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^c Subject had ongoing medical history of liver disorder (e.g., hepatic steatosis, liver disorder, and/or hepatic function abnormal).

^d 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^e Insulin-dependent T2D subject.

^f 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^g Non-diabetic.

^h 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

The severity of liver fibrosis based on the ELF test was stable or improved from baseline in the majority of subjects (10/12, 83.3%) after treatment (Table 10). An increase in liver fibrosis from moderate to severe was detected in Subjects 826-001-001, who had a 204-day break in study drug treatment.

Table 10: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on the Severity of Liver Fibrosis – individual results

Subject ID	Severity of Liver Fibrosis Based on ELF Test ^a					
	Baseline	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)
826-001-001 ^{b,c}	Mod	Mod	Mod	Mod	Sev	Sev
826-001-002 ^c	Mod	Mod	Mod	---	---	---
826-001-003 ^{d,e}	Mod	Mod	Mod	Mod	Mod	Mod
826-001-004 ^f	NTM	Mod	NTM	NTM	NTM	NA
826-001-005 ^{c,g,h}	Mod	Mod	NTM	Mod	NTM	NTM
826-001-006 ^{c,h}	Mod	NTM	NTM	NTM	NTM	---
826-001-007 ^{c,d}	Sev	Sev	Sev	Sev	NA	Sev
826-001-009 ^c	Mod	Mod	Mod	Mod	Mod	Mod
826-001-012	Sev	Sev	Sev	Sev	Sev	Sev
826-001-013 ^f	Mod	Mod	Mod	Mod	Mod	Mod
826-001-014 ^{c,e}	Sev	Sev	Sev	---	---	---
826-001-015 ^c	Mod	Mod	Mod	Mod	Mod	Mod

--- = no data available; ELF = Enhanced Liver Fibrosis; EP = Extension Period; ID = identification number; NTM = normal to mild; Mod = moderate; Sev = severe.

5 ^a ELF test score: None to mild fibrosis < 7.7; moderate fibrosis ≥ 7.7 to < 9.8; and severe fibrosis ≥ 9.8.

^b 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

10 ^c Subject had ongoing medical history of liver disorder (e.g., hepatic steatosis, liver disorder, and/or hepatic function abnormal).

^d 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^e Insulin-dependent T2D subject.

15 ^f 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^g Non-diabetic.

^h 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

20 These results provide evidence that treatment with sodium 2-(3-pentylphenyl)acetate for a period of more than 48 weeks, and preferably for at least 60 weeks, leads to significant improvement of liver histology (more specifically liver stiffness) in ALMS patients, and that treatment interruption is associated with deterioration of liver histology, as assessed using various parameters.

Example 3: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on heart histology

Cardiomyopathy is a well-recognized feature in infants as well as in older children and adults with ALMS. Histopathology and cardiac Magnetic Resonance Imaging (MRI) analyses have revealed interstitial fibrosis affecting the myocardium in ALMS patients (Brofferio *et al.*, *Mol Genet Metab.* 2017 Aug; 121(4): 336-343).

A) Cardiac Magnetic Resonance Imaging of Left Ventricular Function

The effect of sodium 2-(3-pentylphenyl)acetate on heart histology in ALMS patients was assessed by measuring left ventricular function (LVF). LVF measurements permit to quantify how well the left ventricle is able to pump blood through the body with each heartbeat, and is also a prognostic factor in acute myocardial infarction.

The results depicted in Table 11A demonstrate a statistically significant mean increase of 7.75 mL ($p = 0.0294$) in left ventricular end-diastolic volume (LVEDV), and a strong trend toward an increase in left ventricular end-systolic volume (LVESV), from baseline after 60 weeks of treatment.

Table 11A: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on Magnetic Resonance Imaging Assessment of LVESV and LVEDV

Statistics	Change from Baseline			
	LVESV (mL)		LVEDV (mL)	
	Week 24	EP Week 36 (Week 60)	Week 24	EP Week 36 (Week 60)
N	10	4	10	4
Mean (SD)	0.70 (9.650)	3.75 (2.500)	4.40 (16.574)	7.75 (3.948)
Median	3.00	3.50	5.00	8.50
PT P-value	0.8237	0.0577	0.4229	0.0294
PT 95% CI	-6.20, 7.60	-0.23, 7.73	-7.46, 16.26	1.47, 14.03
SW P-value	0.6121	0.9109	0.1927	0.2498
WS P-value	0.8340	0.1250	0.5156	0.1250

CI = confidence interval; LVEDV = left ventricular end-diastolic volume; LVESV = left ventricular end-systolic volume; PT = paired t-test; SD = standard deviation; SW = Shapiro-Wilk test; WS = Wilcoxon signed-rank test.

Cardiac MRI of left ventricular function was variable at baseline (Table 11B). LVEDV increased from baseline in the majority of subjects (10/12, 83.3%) after treatment, with increases ranging from 2 to 42 mL. LVESV increased or did not change from baseline in the majority of subjects (9/12, 75.0%) after treatment, with increases ranging from 1 to 15 mL. Interestingly,

subjects 826-001-002 and 826-001-004 had LVEDV and LVESV below normal at baseline, but within the normal range after the treatment period. Normalization of LVESV after treatment also occurred in subject 826-001-015, which suggests that sodium 2-(3-pentylphenyl)acetate may be useful for normalizing left ventricular function in ALMS patients with impaired (i.e. lower than normal) left ventricular function (e.g., LVEDV and/or LVESV).

B) Cardiac Magnetic Resonance Imaging of Myocardial Fibrosis

The effect of sodium 2-(3-pentylphenyl)acetate on heart histology in ALMS patients was also assessed by measuring short-axis (plane) longitudinal relaxation time (SAX T1). A decrease in relaxation time reflects an improvement in heart histology, such as a decrease of myocardial fibrosis, which reduces the risk of cardiac failure.

The results depicted in Table 12 demonstrate statistically significant mean decreases in Basal SAX T1 (84.75 ms; $p = 0.0274$) and Mid SAX T1 (54.63 ms; $p = 0.0349$) from baseline after 60 weeks of treatment with sodium 2-(3-pentylphenyl)acetate.

Table 12: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on Magnetic Resonance Imaging Assessment of SAX T1

Statistics	Change from Baseline			
	Basal SAX T1 (ms)		Mid SAX T1 (ms)	
	Week 24	EP Week 36 (Week 60)	Week 24	EP Week 36 (Week 60)
N	9	4	9	4
Mean (SD)	-10.67 (44.172)	-84.75 (42.003)	-4.11 (24.427)	-54.63 (29.722)
Median	-1.50	-80.50	0.00	-51.00
PT P-value	0.4894	0.0274	0.6272	0.0349
PT 95% CI	-44.62, 23.29	-151.59, -17.91	-22.89, 14.67	-101.92, -7.33
SW P-value	0.3835	0.9331	0.4701	0.8985
WS P-value	0.4961	0.1250	0.7422	0.1250

Example 4: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on kidney histology

Renal disease is a hallmark of ALMS, starting early and progressing with age, leading to a high prevalence of advanced chronic kidney disease (CKD) at young age in ALMS patients (Baig *et al.*, *Nephrol Dial Transplant.* 2018 Oct 10. doi: 10.1093/ndt/gfy293. [Epub ahead of print]).

A) Albumin-to-creatinine ratio (ACR)

Albuminuria, the increase in excretion of urinary albumin, is marker of kidney damage and is assessed by measuring the ACR. The effect of sodium 2-(3-pentylphenyl)acetate on kidney

histology/damage in ALMS patients was assessed by measuring the ACR. The results reported in Table 13.

Table 13: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on ACR (change from baseline)

Statistics	Change from Baseline ACR (mg/mmol)				
	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)
N	12	11	10	10	9
Mean (SD)	10.08 (20.848)	4.96 (14.993)	6.19 (16.707)	13.30 (28.301)	21.32 (44.461)
Median	0.90	0.30	1.25	1.30	1.60
PT P-value	0.1220	0.2979	0.2714	0.1714	0.1882
PT 95% CI	-3.16, 23.33	-5.11, 15.04	-5.76, 18.14	-6.95, 33.55	-12.90, 55.50
SW P-value	0.0004	0.0010	0.0005	0.0005	0.0001
WS P-value	0.2334	0.9658	0.2324	0.2754	0.0117

- 5 ACR = albumin/creatinine ratio; CI = confidence interval; EP = Extension Period; PT = paired t-test; SD = standard deviation; SW = Shapiro-Wilk test; WS = Wilcoxon signed-rank test.

10 ACR was variable at baseline, ranging from 0.7 to 44.5 ng/L (Table 14), with 2 subjects (Subjects 826-001-007 and 826-001-013) having more advanced disease (> 33.9 mg/mmol). Of note, Subject 826-001-007 had an ongoing medical history of microalbuminuria, and Subject 826-001-013 had an ongoing medical history of hypertension. Of note, the largest increases in ACR from baseline occurred in Subjects 826-001-003 (13.8 mg/mmol), 826-001-007 (133.8 mg/mmol), and 826-001-013 (43.9 mg/mmol), each of whom had a break in study drug treatment (32, 32, and 30 days, respectively) between Week 24 and the start of the EP. This suggests that continuous treatment with sodium 2-(3-pentylphenyl)acetate may limit the progression of kidney damage/injury in the subjects.

Table 14: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on ACR – individual results

Subject ID	ACR (mg/mmol) ^a					
	Baseline	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)
826-001-001 ^b	6.3	4.3	4.2	7.5	6.2	6.1
826-001-002	17.6	22.5	15.5	---	---	---
826-001-003 ^{c,d}	13.7	24.3	14.5	18.0	21.6	21.9
826-001-004 ^e	17.7	14.5	10.7	7.9	6.7	19.2
826-001-005 ^{f,g}	0.7	0.4	---	2.0	2.1	< 2.3
826-001-006 ^g	4.4	< 2.3	2.2	2.2	0.8	---
826-001-007 ^c	44.5	89.2	77.0	95.0	111.7	178.3
826-001-009	1.7	< 2.3	< 2.3	< 2.3	0.7	1.9
826-001-012 ^h	6.9	15.1	13.2	8.6	12.9	8.6
826-001-013 ^e	41.5	102.9	77.4	56.3	106.5	85.4
826-001-014 ^{d,h}	18.6	15.6	10.2	---	---	---
826-001-015 ^h	1.1	< 2.3	1.4	0.6	< 2.3	< 2.3

--- = no data available; ACR = albumin/creatinine ratio; EP = Extension Period; ID = identification number.

^a ACR < 3.39 mg/mmol = normal; ACR 3.39 to 33.9 mg/mmol = early kidney disease (microalbuminuria); and ACR > 33.9 mg/mmol = more advanced kidney disease (macroalbuminuria).

^b 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^c 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^d Insulin-dependent T2D subject.

^e 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^f Non-diabetic.

^g 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^h Subject had ongoing medical history of chronic kidney disease.

B) Biomarkers of kidney injury

Urinary proteins including monocyte chemoattractant protein 1 (MCP-1), kidney injury molecule-1 (KIM-1), clusterin, cystatin C, and osteopontin have been shown to be indicators of kidney injury. The levels of these markers was assessed at baseline and after 24 weeks of treatment with sodium 2-(3-pentylphenyl)acetate in ALMS patients, and the results are reported in Table 15.

Table 15: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on Urinary Kidney Toxicity Biomarkers

Urinary Kidney Toxicity Biomarkers ^a	Mean Fold Change from Baseline to Week 24 (%)	SD	P-Value (One-tailed)	P-Value (Two-tailed)
MCP-1	0.85 (-15%)	0.59	0.02	0.05
Clusterin	0.66 (-34%)	0.43	0.03	0.06
KIM-1	0.67 (-33%)	0.33	0.02	0.03
Cystatin C	0.75 (-25%)	0.29	0.01	0.02
Osteopontin	0.82 (-18%)	0.34	0.03	0.06

KIM-1 = kidney injury marker-1; MCP-1 = monocyte chemoattractant protein-1; SD = standard deviation.

^a The kidney toxicity panel tested the level of biomarkers in urine samples; subject results were generated as the ratio of the given analyte/creatinine level (ng/nmol).

Example 5: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on metabolic parameters

ALMS is associated with several metabolic abnormalities. Severe insulin resistance, hyperinsulinemia, and impaired glucose tolerance often present in very early childhood and are frequently accompanied by acanthosis nigricans. T2DM develops in childhood, adolescence, or adulthood, with a mean age of onset at 16 years. Children with ALMS also often have high lipid levels at an early age.

A) Glycated Hemoglobin (HbA1c)

Glycated hemoglobin (HbA1c) is measured primarily to determine the three-month average blood sugar level, and is used as a diagnostic test for diabetes mellitus and as an assessment test for glycemic control in people with diabetes. HbA1c was assessed in ALMS patients treated with sodium 2-(3-pentylphenyl)acetate. There was a statistically significant mean decrease of 0.53% ($p = 0.0144$) in HbA1c from baseline after 12 weeks of treatment (Table 16).

Table 161: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on the Change from Baseline in Glycated Hemoglobin

Statistics	Change from Baseline HbA1c (%)					
	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)	EP Week 48 (Week 72)
N	12	12	10	10	9	3
Mean (SD)	-0.53 (0.627)	-0.24 (0.834)	0.24 (1.880)	-0.28 (1.417)	-0.18 (0.998)	0.13 (0.153)
Median	-0.55	-0.05	0.00	-0.30	-0.10	0.10
PT P-value	0.0144	0.3370	0.6958	0.5476	0.6078	0.2697
PT 95% CI	-0.92, -0.13	-0.77, 0.29	-1.10, 1.58	-1.29, 0.73	-0.95, 0.59	-0.25, 0.51
SW P-value	0.3785	0.7726	0.1014	0.0141	0.7258	0.6369
WS P-value	0.0225	0.4746	1.0000	0.0781	0.7148	0.5000

CI = confidence interval; HbA1c = glycated hemoglobin; EP = Extension Period; PT = paired t-test; SD = standard deviation; SW = Shapiro-Wilk test; WS = Wilcoxon signed-rank test.

HbA1c was variable at baseline, ranging from 4.8% to 11.9% (Table 17). The lowest baseline HbA1c occurred in Subject 826-001-005 who did not have T2D, and the highest baseline HbA1c occurred in Subjects 826-001-003 and 826-001-014 who had insulin-dependent T2D. HbA1c decreased or did not change from baseline in the majority of subjects (8/12, 66.7%) after treatment. Of note, Subjects 826-001-007, 826-001-009, and 826-001-014 had their HbA1c reduced by $\geq 1\%$ below baseline after study drug treatment; for 2 of these subjects (826-001-007 and 826-001-014), baseline HbA1c was $> 9\%$. In contrast, Subject 826-001-001, who had a 204-day break in study drug treatment between Week 24 and the start of the EP, had its HbA1c increased by $\geq 1\%$ above baseline by the last study visit.

Table 17: By-Subject Listing of Glycated Hemoglobin

Subject ID	HbA1c (%) ^a						
	Baseline	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)	EP Week 48 (Week 72)
826-001-001 ^b	7.4	6.5	8.6	12	10.6	9.1	---
826-001-002	5.2	5.7	6.1	---	---	---	---
826-001-003 ^{c,d,e}	10.8	10.1	11.1	12.7	10.6	11.2	11.1
826-001-004 ^f	5.0	5.3	5.4	5.1	4.9	5.1	5.0
826-001-005 ^{g,h}	4.8	5.0	4.8	5.4	4.7	5.0	4.9
826-001-006 ^h	6.1	5.7	5.6	5.4	5.7	---	---
826-001-007 ^c	9.2	8.2	9.1	7.5	6.8	7.5	---
826-001-009	6.6	5.5	5.4	5.4	5.4	5.4	---
826-001-012	6.9	6.7	7.0	7.3	6.5	6.8	---
826-001-013 ^f	6.5	6.1	6.2	6.4	6.3	6.4	---
826-001-014 ^d	11.9	10.6	10.0	---	---	---	---
826-001-015	7.7	6.4	6.6	6.2	6.7	6.8	---

--- = no data available; EP = Extension Period; HbA1c = glycated hemoglobin; ID = identification number; T1D = type 1 diabetes; T2D = type 2 diabetes.

^a Normal without diabetes ≤ 5.6%; normal with diabetes < 6.5%.

^b 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^c 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^d Insulin-dependent T2D subject.

^e Also had T1D.

^f 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^g 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^h Non-diabetic.

B) Fasting Plasma Glucose (FPG)

The effect of sodium 2-(3-pentylphenyl)acetate on FPG levels was assessed, and the results are presented in Table 18.

Table 18: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on the Change from Baseline in Fasting Plasma Glucose

Statistics	Change from Baseline FPG (mmol/L)					
	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)	EP Week 48 (Week 72)
N	11	12	10	10	9	3
Mean (SD)	0.30 (4.958)	0.33 (3.594)	0.63 (5.234)	0.70 (4.571)	1.49 (5.380)	-0.93 (2.065)
Median	-0.40	0.30	-0.10	-0.10	0.00	0.00
PT P-value	0.8450	0.7600	0.7123	0.6397	0.4305	0.5157
PT 95% CI	-3.03, 3.63	-1.96, 2.61	-3.11, 4.37	-2.57, 3.97	-2.65, 5.62	-6.06, 4.20
SW P-value	0.0799	0.4366	0.0755	0.2156	0.2299	0.2318
WS P-value	0.5303	0.7168	0.8203	0.9336	0.6406	1.0000

CI = confidence interval; EP = Extension Period; FPG = fasting plasma glucose; PT = paired t-test; SD = standard deviation; SW = Shapiro-Wilk test; WS = Wilcoxon signed-rank test.

- 5 FPG was variable at baseline, ranging from 4.7 to 20.0 mmol/L (Table 19). The lowest baseline FPG occurred in Subject 826-001-005 who did not have T2D, and the highest baseline FPG occurred in Subjects 826-001-003 and 826-001-014 who had insulin dependent T2D. Of note, the largest increases in FPG from baseline occurred in Subjects 826-001-001 (7.4 mmol/L) and 826-001-007 (7.9 mmol/L), each of whom had breaks in study drug treatment (204 and 10 32 days, respectively) between Week 24 and the start of the EP.

Table 19: By-Subject Listing of Fasting Plasma Glucose

Subject ID	FPG (mmol/L) ^a						
	Baseline	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)	EP Week 48 (Week 72)
826-001-001 ^b	7.5	5.0	13.5	19.9	13.8	14.9	---
826-001-002	5.5	4.7	6.1	---	---	---	---
826-001-003 ^{c,d,e}	15.8	22.8	12.9	18.0	23.3	22.7	12.5
826-001-004 ^f	5.0	4.6	4.9	4.8	3.8	5.0	5.5
826-001-005 ^{g,h}	4.7	4.3	4.7	4.3	4.7	4.6	4.7
826-001-006 ^h	6.5	5.3	5.7	5.2	6.9	---	---
826-001-007 ^c	5.9	16.9	11.1	9.1	10.2	13.8	---
826-001-009	5.8	7.0	4.8	4.4	4.8	5.3	---
826-001-012	5.9	5.5	7.2	6.5	5.7	4.7	---
826-001-013 ^f	6.6	---	7.4	6.6	6.2	8.6	---
826-001-014 ^d	20.0	17.6	22.6	---	---	---	---
826-001-015	14.3	6.5	6.5	5.5	5.6	5.3	---

--- = no data available; EP = Extension Period; FPG = fasting plasma glucose; ID = identification number; T1D = type 1 diabetes; T2D = type 2 diabetes.

^a Normal FPG < 5.5 mmol/L.

- 15 ^b 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^c 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^d Insulin-dependent T2D subject.

^e Also had T1D.

5 ^f 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^g 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^h Non-diabetic.

10

C) Fasting insulin

The effect of sodium 2-(3-pentylphenyl)acetate on fasting insulin levels was assessed, and the results are presented in Table 20.

Table 20: Effect of 800 mg 2-(3-pentylphenyl)acetate on the Change from Baseline in Fasting Insulin

15

Statistics	Change from Baseline Fasting Insulin (pmol/L)					
	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)	EP Week 48 (Week 72)
N	12	12	10	9	8	3
Mean (SD)	-18.92 (1668.350)	-339.08 (1120.347)	-920.20 (2685.081)	-1371.78 (4128.701)	-1191.63 (4654.572)	-3933.00 (7237.565)
Median	9.00	-86.00	-53.50	-24.00	7.00	193.00
PT P-value	0.9694	0.3169	0.3067	0.3481	0.4925	0.4459
PT 95% CI	-1078.94, 1041.10	-1050.92, 372.75	-2840.99, 1000.59	-4545.38, 1801.82	-5082.94, 2699.69	-21912.10, 14046.11
SW P-value	0.0022	0.0001	0.0001	0.0001	0.0001	0.0139
WS P-value	0.9658	0.4238	0.2324	0.5703	0.8438	1.0000

CI = confidence interval; EP = Extension Period; PT = paired t-test; SD = standard deviation; SW = Shapiro-Wilk test; WS = Wilcoxon signed-rank test.

Fasting insulin was variable at baseline, ranging from 110 to 12,750 pmol/L (Table 21). All but 1 non-diabetic subject (825-001-005) had fasting insulin levels indicative of insulin resistance, with the largest baseline level occurring in an insulin-dependent subject (826-001-003) with both T1D/T2D. Of note, Subject 826-001-003 had a baseline fasting insulin of 12,750 pmol/L that decreased by nearly 30% after 24 weeks and by > 96% after 72 weeks of study drug treatment; this subject had insulin dependent T2D. The largest increases in fasting insulin from baseline occurred in Subjects 826-001-001 (420 pmol/L), 826-001-004 (298 pmol/L), 826-001-007 (1,970 pmol/L), and 826-001-013 (1,160 pmol/L), each of whom had a break in treatment (204, 30, 32, and 30 days, respectively) between Week 24 and the start of the EP.

20

25

Table 21: By-Subject Listing of Fasting Insulin

Subject ID	Fasting Insulin (pmol/L) ^a						
	Baseline	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)	EP Week 48 (Week 72)
826-001-001 ^b	485	105	414	425	880	905	---
826-001-002	406	467	265	---	---	---	---
826-001-003 ^{c, d, e}	12750	8400	8900	4200	381	202	460
826-001-004 ^f	302	320	469	370	266	---	600
826-001-005 ^{g, h}	110	135	66	71	92	181	303
826-001-006 ^h	459	346	358	412	435	---	---
826-001-007 ^c	230	2190	450	330	2200	---	---
826-001-009	595	3360	397	305	322	300	---
826-001-012	315	315	670	441	464	258	---
826-001-013 ^f	420	396	225	157	483	1580	---
826-001-014 ^d	215	247	222	---	---	---	---
826-001-015	292	71	74	45	59	38	---

--- = no data available; EP = Extension Period; ID = identification number; T1D = type 1 diabetes; T2D = type 2 diabetes.

^a A fasting insulin level > 174 pmol/L is considered insulin resistance.

^b 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^c 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^d Insulin-dependent T2D subject.

^e Also had T1D.

^f 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^g 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^h Non-diabetic.

D) C-peptide

The effect of sodium 2-(3-pentylphenyl)acetate on C-peptide levels was assessed, and the results are presented in Table 22.

Table 22: Effect of 800 mg 2-(3-pentylphenyl)acetate on the Change from Baseline in C-peptide

Statistics	Change from Baseline C-Peptide (pmol/L)					
	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)	EP Week 48 (Week 72)
N	12	12	10	9	8	3
Mean (SD)	473.50 (2122.903)	41.25 (1083.324)	-350.90 (1144.884)	-286.67 (891.898)	219.88 (1547.287)	810.00 (912.692)
Median	102.50	84.50	6.00	-40.00	-31.00	737.00
PT P-value	0.4560	0.8974	0.3578	0.3632	0.6997	0.2641
PT 95% CI	-875.0, 1822.0	-647.0, 729.6	-1170.0, 468.1	-972.0, 398.9	-1074.0, 1513.0	-1457.0, 3077.0
SW P-value	0.0081	0.1961	0.3750	0.5383	0.1249	0.8676
WS P-value	0.3804	0.7334	0.6250	0.5703	1.0000	0.5000

CI = confidence interval; EP = Extension Period; PT = paired t-test; SD = standard deviation;
SW = Shapiro-Wilk test; WS = Wilcoxon signed-rank test.

C-peptide was variable at baseline, ranging from 94 to 3,895 pmol/L (Table 23). Most subjects had baseline C-peptide levels outside the normal range. The lowest baseline C-peptide occurred in the 2 insulin-dependent T2D subjects (826-001-003 and 826-001-014), including the 1 subject (826-001-003) with T1D. Of note, low C-peptide levels had been reported to be a biomarker for characterizing at-risk subjects with T1D. Decreases in C-peptide from baseline ranged from 64 to 1,713 pmol/L. Of note, the largest increases in C-peptide from baseline occurred in Subjects 826-001-001 (817 pmol/L), 826-001-004 (1.757 pmol/L), 826-001-005 (737 pmol/L), and 826-001-007 (3,578 pmol/L), each of whom had a break in study drug treatment (204, 30, 39, and 32 days, respectively) between Week 24 and the start of the EP.

Table 23: By-Subject Listing of C-Peptide

Subject ID	C-Peptide (pmol/L)						
	Baseline	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)	EP Week 48 (Week 72)
826-001-001 ^b	2143	988	1771	2138	2949	2960	---
826-001-002	1465	1807	2080	---	---	---	---
826-001-003 ^{c, d, e}	178	227	139	195	222	282	114
826-001-004 ^f	2199	2639	3332	3618	2589	---	3956
826-001-005 ^{g, h}	846	876	743	864	806	1035	1583
826-001-006 ^h	1644	1850	1939	1862	2284	---	---
826-001-007 ^c	1907	6065	3342	2330	5485	---	---
826-001-009	2432	7570	2570	1925	2077	2148	---
826-001-012	3521	3677	4735	2859	2348	2755	---
826-001-013 ^f	3895	---	1798	1306	2769	3729	---
826-001-014 ^d	94	116	125	---	---	---	---
826-001-015	2820	942	1065	979	1054	1107	---

--- = no data available; EP = Extension Period; ID = identification number; T1D = type 1 diabetes; T2D = type 2 diabetes.

^a C-peptide normal range: 364.1-1456.4 pmol/L.

^b 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^c 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^d Insulin-dependent T2D subject.

^e Also had T1D.

^f 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^g 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^h Non-diabetic.

E) Homeostasis Model Assessment for Steady State Beta-Cell Function Based on C-Peptide and Fasting Plasma Glucose (HOMA-B [C-Peptide/FPG])

The effect of sodium 2-(3-pentylphenyl)acetate on HOMA-B (C-peptide/FPG) was assessed, and the results are presented in Table 24.

Table 24: Effect of 800 mg 2-(3-pentylphenyl)acetate on the Change from Baseline in HOMA-B Based on C-Peptide and Fasting Plasma Glucose

Statistics	Change from Baseline HOMA-B Based on C-Peptide and FPG					
	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)	EP Week 48 (Week 72)
N	11	12	10	9	8	3
Mean (SD)	52.58 (65.820)	-1.60 (78.459)	1.70 (102.620)	24.57 (96.750)	1.42 (62.993)	60.17 (51.676)
Median	35.60	0.60	16.50	-1.90	8.00	89.40
PT P-value	0.0243	0.9450	0.9594	0.4681	0.9508	0.1813
PT 95% CI	8.36, 96.80	-51.45, 48.25	-71.71, 75.11	-49.80, 98.94	-51.24, 54.09	-68.20, 188.54
SW P-value	0.2817	0.8770	0.6708	0.0395	0.8386	0.0222
WS P-value	0.0186	0.9697	1.0000	0.8203	1.0000	0.2500

CI = confidence interval; EP = Extension Period; FPG = fasting plasma glucose; HOMA-B = homeostasis model assessment for steady state beta-cell function; PT = paired t-test; SD = standard deviation; SW = Shapiro-Wilk test; WS = Wilcoxon signed-rank test.

HOMA-B (C-peptide/FPG) was variable at baseline, ranging from 2.4 to 306.4 (Table 25), with the lowest baseline HOMA-B (C-peptide/FPG) occurring in the 2 insulin-dependent T2D subjects (826-001-003 and 826-001-014). HOMA-B (C-peptide/FPG) increased from baseline in most subjects (9/12, 75.0%) after treatment. Of note, the largest reductions in HOMA-B

(C-peptide/FPG) occurred in Subjects 826-001-001 (62.4), 826-001-007 (33.4), and 826-001-013 (96.7), each of whom had a break in study drug treatment (204, 32, and 30 days, respectively) between Week 24 and the start of the EP.

Table 25: By-Subject Listing of HOMA-B Based on C-Peptide and Fasting Plasma Glucose

Subject ID	HOMA-B Based on C-Peptide and FPG						
	Baseline	Week 12	Week 24	EP Week 12 (Week 36)	EP Week 24 (Week 48)	EP Week 36 (Week 60)	EP Week 48 (Week 72)
826-001-001 ^a	139.7	162.8	51.3	43.8	82.5	77.3	---
826-001-002	180.3	280.3	193.8	---	---	---	---
826-001-003 ^{b, c, d}	5.8	4.1	6.9	5.1	3.9	5.0	6.3
826-001-004 ^e	288.0	382.8	405.1	446.7	538.6	---	377.4
826-001-005 ^{f, g}	164.5	200.1	150.4	198.2	159.1	197.2	255.1
826-001-006 ^g	145.4	228.5	207.4	237.6	168.6	---	---
826-001-007 ^b	192.6	159.4	117.4	110.7	---	159.2	---
826-001-009	238.0	442.9	347.4	331.6	297.8	254.8	---
826-001-012	306.4	356.8	284.1	221.8	239.0	379.7	---
826-001-013 ^e	276.3	---	124.6	119.2	234.2	179.6	---
826-001-014 ^c	2.4	3.5	2.5	---	---	---	---
826-001-015	76.2	96.5	105.5	135.2	137.7	158.1	---

--- = no data available; EP = Extension Period; FPG = fasting plasma glucose; HOMA-B = homeostasis model assessment for steady state beta-cell function; ID = identification number; T1D = type 1 diabetes; T2D = type 2 diabetes.

^a 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^b 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^c Insulin-dependent T2D subject.

^d Also had T1D.

^e 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^f 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^g Non-diabetic.

Example 6: Effect of 800 mg sodium 2-(3-pentylphenyl)acetate on adipose tissue

Histological examination of adipocyte tissue in an ALMS subject (before study drug treatment) was characterized by hypertrophy and coalescence of adipocytes, forming giant vesicular vacuolation/steatosis (**FIG. 2A**). After 24 weeks of treatment with 800 mg 2-(3-

pentyphenyl)acetate, more distinct adipocytes were seen that were smaller in size with no observed coalescence (**FIG. 2B**).

Average adipocyte area decreased from baseline in the majority of subjects (6/9, 66.7%) after 24 weeks of treatment (Table 26). Decreases in average adipocyte area from baseline ranged from 11% to 26%. Of note, the largest increase in average adipocyte area from baseline occurred in Subject 826-001-012 (25%), who had ongoing medical histories of hypothyroidism, myocardial ischemia, T2D, chronic kidney disease, and dyslipidemia. This subject was also characterized as obese with a baseline BMI of 38.13 kg/m².

Table 26: Effect of 800 mg sodium 2-(3-pentyphenyl)acetate on Average Adipocyte Area

Subject ID	Average Adipocyte Area (μm ²)		
	Baseline	Week 24	% Change from Baseline
826-001-001 ^{a, b}	NS	6017.1	---
826-001-002 ^b	5836.4	5898.3	+1%
826-001-003 ^{b, c, d}	7286.3	6133.7	-16%
826-001-004 ^{b, e}	5696.8	4197.7	-26%
826-001-005 ^{f, g}	4997.4	5195.1	+4%
826-001-006 ^g	5867.0	5178.6	-12%
826-001-007 ^{b, c}	5599.6	4319.0	-23%
826-001-009 ^b	6790.6	6059.9	-11%
826-001-012 ^b	6547.5	8182.0	+25%
826-001-013 ^{b, e}	5962.1	4792.1	-20%
826-001-014 ^{b, d}	4519.7	NS	---
826-001-015 ^b	NS	4197.3	---
Mean	6064.9	5550.7	-9%
Median	5867.0	5195.1	-12%

--- = no data available; ID = identification number; NS = no sample; T2D = type 2 diabetes.

^a 204-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^b Subject had ongoing T2D and/or other metabolic disorders.

^c 32-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^d Insulin-dependent T2D subject.

^e 30-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

^f Non-diabetic.

^g 39-day break in study drug treatment between Week 24 and EP Day 0 (first day of EP study drug treatment).

Baseline histological examination of an adipocyte tissue artery (perivascular adipose tissue) in an ALMS subject was characterized by signs of dystrophy, homogenized blurred cytoplasm in smooth muscle cells, and nuclei with irregular shape (**FIG. 3A**). After 24 weeks of

study drug treatment with 800 mg sodium 2-(3-pentylphenyl)acetate, the adipocyte tissue artery looked more normal (**FIG. 3B**).

The scope of the claims should not be limited by the embodiments set forth in the examples but should be given the broadest interpretation consistent with the description as a whole.

5

WHAT IS CLAIMED IS:

1. A method for improving at least one of liver histology, heart histology, kidney histology, adipose tissue histology and glycemic control in a patient suffering from ALMS, said method comprising administering to said patient a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg for a treatment period of more than 48 weeks, and wherein the administration is not interrupted for 15 days or more during said treatment period.
2. The method of claim 1, wherein the treatment period is of more than 54 weeks.
3. The method of claim 1, wherein the treatment period is of more than 60 weeks.
4. The method of any one of claims 1 to 3, wherein the administration is not interrupted for 30 days or more.
5. The method of any one of claims 1 to 4, wherein said method is for improving at least liver histology.
6. The method of claim 5, wherein improving liver histology comprises reducing liver stiffness.
7. The method of claim 6, wherein the liver stiffness is reduced by at least 2 kPa relative to prior to the administration, as measured by transient elastography.
8. The method of claim 7, wherein the liver stiffness is reduced by at least 2.25 kPa relative to prior to the administration, as measured by transient elastography.
9. The method of any one of claims 5 to 8, wherein improving liver histology comprises reducing the Metavir score by at least one grade or stage.
10. The method of any one of claims 1 to 9, wherein said method is for improving at least heart histology.
11. The method of any one of claims 1 to 10, wherein improving heart histology comprises increasing left ventricular function (LVF)
12. The method of claim 11, wherein the LVF comprises left ventricular end-diastolic volume (LVEDV) and/or left ventricular end-systolic volume (LVESV).
13. The method of claim 11, wherein the LVF comprises LVEDV.

14. The method of claim 12 or 13, wherein the method is for increasing LVEDV by at least 6 ml relative to prior to the administration, as measured by cardiac Magnetic Resonance Imaging (MRI).
- 5 15. The method of any one of claims 10 to 14, wherein improving heart histology comprises reducing short-axis (plane) longitudinal relaxation time (SAX T1).
16. The method of claim 15, wherein the SAX T1 is Basal SAX T1 and/or Mid SAX T1.
17. The method of claim 16, wherein the method is for reducing Basal SAX T1 by at least 40 ms relative to prior to the administration, as measured by cardiac MRI.
- 10 18. The method of claim 16 or 17, wherein the method is for reducing Mid SAX T1 by at least 25 ms relative to prior to the administration, as measured by cardiac MRI.
19. The method of any one of claims 1 to 18, wherein said method is for improving at least kidney histology.
20. The method of any one of claims 1 to 19, wherein improving kidney histology comprises restricting kidney damage or injury.
- 15 21. The method of claim 19 or 20, wherein improving kidney histology comprises reducing the levels of one or more biomarkers of kidney injury relative to prior to the administration.
22. The method of claim 21, wherein the one or more biomarkers of kidney injury are monocyte chemoattractant protein 1 (MCP-1), kidney injury molecule-1 (KIM-1), clusterin, cystatin C and osteopontin.
- 20 23. The method of claim 22, wherein the method is for reducing the levels of said one or more biomarkers by at least 10%.
24. The method of any one of claims 1 to 23, wherein said method is for improving at least adipose tissue histology.
- 25 25. The method of claim 24, wherein improving adipose tissue histology comprises reducing average adipocyte area.
26. The method of claim 25, wherein the method is for reducing average adipocyte area by at least 10%.
27. The method of any one of claims 1 to 26, wherein said method is for improving at least glycemic control.

28. The method of any one of claims 1 to 27, wherein improving glycemic control comprises reducing glycated hemoglobin (HbA1c).
29. The method of claim 28, wherein the subject has an HbA1c of more than 9% prior to administration.
- 5 30. The method of claim 28 or 29, wherein the method is for reducing HbA1c by at least 1% (absolute).
31. The method of any one of claims 1 to 30, wherein improving glycemic control comprises increasing the homeostasis Model Assessment for Steady State Beta-Cell Function Based on C-Peptide and Fasting Plasma Glucose (HOMA-B [C-Peptide/FPG]).
- 10 32. The method of claim 31, wherein said method is for increasing HOMA-B [C-Peptide/FPG] by at least 20.
33. A method for improving glycemic control in an ALMS patient with diabetes, said method comprising administering to said patient a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable
15 excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
34. The method of claim 33, wherein the patient has type 2 diabetes.
35. A method for improving liver function in an ALMS patient with liver disease, said method comprising administering to said patient a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable
20 excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
36. The method of claim 35, wherein the liver disease comprises liver fibrosis.
37. The method of claim 36, wherein the patient has fibrosis stage F2, F3 or F4 according to the
25 Metavir scoring system.
38. A method for improving cardiac function in an ALMS patient, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable
30 excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

39. The method of claim 38, wherein the cardiac function is left ventricular function (LVF) and/or short-axis (plane) longitudinal relaxation time (SAX T1).
40. The method of claim 39, wherein the LVF comprises left ventricular end-diastolic volume (LVEDV) and/or left ventricular end-systolic volume (LVESV).
- 5 41. The method of claim 39 or 40, wherein the patient has a lower than normal LVF.
42. The method of claim 41, wherein (i) the patient is a male and has a LVEDV of less than 106 mL and/or a LVESV of less than 26 mL; or (ii) the patient is a female and has a LVEDV of less than 86 mL and/or a LVESV of less than 22 mL.
- 10 43. A method for improving kidney function in an ALMS patient suffering from kidney damage or injury, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
- 15 44. The method of claim 43, wherein the patient has higher than normal levels of one or more biomarkers of kidney toxicity.
45. The method of claim 44, wherein the one or more biomarkers of kidney injury are monocyte chemoattractant protein 1 (MCP-1), kidney injury molecule-1 (KIM-1), clusterin, cystatin C and osteopontin.
- 20 46. A method for improving adipose tissue function in an ALMS patient, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
- 25 47. The method of claim 46, wherein the adipose tissue function is perivascular adipose tissue function.
48. The method of any one of claims 33 to 47, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 24 weeks.
- 30 49. The method of claim 48, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 48 weeks.

50. The method of claim 48, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 60 weeks.
51. The method of any one of claims 1 to 50, wherein the daily dose is of about 700 mg to about 900 mg.
- 5 52. The method of claim 51, wherein the daily dose is of about 800 mg.
53. The method of any one of claims 1 to 50, wherein the daily dose is of about 1100 mg to about 1300 mg.
54. The method of claim 53, wherein the daily dose is of about 1200 mg.
55. The method of any one of claims 1 to 54, wherein the pharmaceutical oral formulation
10 comprises sodium 2-(3-pentylphenyl)acetate.
56. The method of any one of claims 1 to 55, wherein the pharmaceutical oral formulation is a capsule or a tablet.
57. The method of any one of claims 1 to 56, wherein the subject has a body mass index (BMI) $\geq 25.0 \text{ kg/m}^2$.
- 15 58. The method of any one of claims 1 to 57, wherein the subject is a male and has a waist circumference $\geq 94 \text{ cm}$, or the subject is a female and has a waist circumference $\geq 80 \text{ cm}$.
59. A pharmaceutical oral formulation for use in improving at least one of liver histology, heart histology, kidney histology, adipose tissue histology and glycemic control in a patient suffering from ALMS, the pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a
20 pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is for administration at a daily dose of about 500 mg to about 1500 mg for a treatment period of more than 48 weeks, and wherein the administration is not interrupted for 15 days or more during said treatment period.
60. The formulation for use of claim 59, wherein the treatment period is of more than 54 weeks.
- 25 61. The formulation for use of claim 59, wherein the treatment period is of more than 60 weeks.
62. The formulation for use of any one of claims 59 to 61, wherein the administration is not interrupted for 30 days or more.
63. The formulation for use of any one of claims 59 to 62, wherein said method is for improving at least liver histology.

64. The formulation for use of claim 63, wherein improving liver histology comprises reducing liver stiffness.
65. The formulation for use of claim 64, wherein the liver stiffness is reduced by at least 2 kPa relative to prior to the administration, as measured by transient elastography.
- 5 66. The formulation for use of claim 65, wherein the liver stiffness is reduced by at least 2.25 kPa relative to prior to the administration, as measured by transient elastography.
67. The formulation for use of any one of claims 63 to 68, wherein improving liver histology comprises reducing the Metavir score by at least one grade or stage.
68. The formulation for use of any one of claims 59 to 67, wherein said method is for improving
10 at least heart histology.
69. The formulation for use of any one of claims 59 to 70, wherein improving heart histology comprises increasing left ventricular function (LVF)
70. The formulation for use of claim 69, wherein the LVF comprises left ventricular end-diastolic volume (LVEDV) and/or left ventricular end-systolic volume (LVESV).
- 15 71. The formulation for use of claim 70, wherein the LVF comprises LVEDV.
72. The formulation for use of claim 70 or 71, wherein the method is for increasing LVEDV by at least 6 ml relative to prior to the administration, as measured by cardiac Magnetic Resonance Imaging (MRI).
73. The formulation for use of any one of claims 68 to 71, wherein improving heart histology
20 comprises reducing short-axis (plane) longitudinal relaxation time (SAX T1).
74. The formulation for use of claim 73, wherein the SAX T1 is Basal SAX T1 and/or Mid SAX T1.
75. The formulation for use of claim 74, wherein the method is for reducing Basal SAX T1 by at least 40 ms relative to prior to the administration, as measured by cardiac MRI.
- 25 76. The formulation for use of claim 74 or 75, wherein the method is for reducing Mid SAX T1 by at least 25 ms relative to prior to the administration, as measured by cardiac MRI.
77. The formulation for use of any one of claims 59 to 76, wherein said method is for improving at least kidney histology.

78. The formulation for use of any one of claims 59 to 77, wherein improving kidney histology comprises restricting kidney damage or injury.
79. The formulation for use of claim 77 or 78, wherein improving kidney histology comprises reducing the levels of one or more biomarkers of kidney injury relative to prior to the administration.
80. The formulation for use of claim 79, wherein the one or more biomarkers of kidney injury are monocyte chemoattractant protein 1 (MCP-1), kidney injury molecule-1 (KIM-1), clusterin, cystatin C and osteopontin.
81. The formulation for use of claim 80, wherein the method is for reducing the levels of said one or more biomarkers by at least 10%.
82. The formulation for use of any one of claims 59 to 81, wherein said method is for improving at least adipose tissue histology.
83. The formulation for use of claim 82, wherein improving adipose tissue histology comprises reducing average adipocyte area.
84. The formulation for use of claim 83, wherein the method is for reducing average adipocyte area by at least 10%.
85. The formulation for use of any one of claims 59 to 84, wherein said method is for improving at least glycemic control.
86. The formulation for use of any one of claims 1 to 85, wherein improving glycemic control comprises reducing glycated hemoglobin (HbA1c).
87. The formulation for use of claim 86, wherein the subject has an HbA1c of more than 9% prior to administration.
88. The formulation for use of claim 86 or 87, wherein the method is for reducing HbA1c by at least 1% (absolute).
89. The formulation for use of any one of claims 59 to 88, wherein improving glycemic control comprises increasing the homeostasis Model Assessment for Steady State Beta-Cell Function Based on C-Peptide and Fasting Plasma Glucose (HOMA-B [C-Peptide/FPG]).
90. The formulation for use of claim 89, wherein said method is for increasing HOMA-B [C-Peptide/FPG] by at least 20.

91. A pharmaceutical oral formulation for use in improving glycemic control in an ALMS patient with diabetes, said pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
92. The formulation for use of claim 91, wherein the patient has type 2 diabetes.
93. A pharmaceutical oral formulation for use in improving liver function in an ALMS patient with liver disease, said pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
94. The formulation for use of claim 93, wherein the liver disease comprises liver fibrosis.
95. The formulation for use of claim 94, wherein the patient has fibrosis stage F2, F3 or F4 according to the Metavir scoring system.
96. A pharmaceutical oral formulation for use in improving cardiac function in an ALMS patient, said pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.
97. The formulation for use of claim 96, wherein the cardiac function is left ventricular function (LVF) and/or short-axis (plane) longitudinal relaxation time (SAX T1).
98. The formulation for use of claim 97, wherein the LVF comprises left ventricular end-diastolic volume (LVEDV) and/or left ventricular end-systolic volume (LVESV).
99. The formulation for use of claim 97 or 98, wherein the patient has a lower than normal LVF.
100. The formulation for use of claim 99, wherein (i) the patient is a male and has a LVEDV of less than 106 mL and/or a LVESV of less than 26 mL; or (ii) the patient is a female and has a LVEDV of less than 86 mL and/or a LVESV of less than 22 mL.
101. A pharmaceutical oral formulation for use in improving kidney function in an ALMS patient suffering from kidney damage or injury, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically

salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

102. The formulation for use of claim 101, wherein the patient has higher than normal levels of one or more biomarkers of kidney toxicity.

103. The formulation for use of claim 102, wherein the one or more biomarkers of kidney injury are monocyte chemoattractant protein 1 (MCP-1), kidney injury molecule-1 (KIM-1), clusterin, cystatin C and osteopontin.

104. A pharmaceutical oral formulation for use in improving adipose tissue function in an ALMS patient, said method comprising administering to said subject a pharmaceutical oral formulation comprising 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof and a pharmaceutically acceptable excipient, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered at a daily dose of about 500 mg to about 1500 mg.

105. The formulation for use of claim 104, wherein the adipose tissue function is perivascular adipose tissue function.

106. The formulation for use of any one of claims 91 to 105, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 24 weeks.

107. The formulation for use of claim 106, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 48 weeks.

108. The formulation for use of claim 106, wherein said 2-(3-pentylphenyl)acetate or a pharmaceutically salt thereof is administered for a treatment period of at least 60 weeks.

109. The formulation for use of any one of claims 59 to 108, wherein the daily dose is of about 700 mg to about 900 mg.

110. The formulation for use of claim 109, wherein the daily dose is of about 800 mg.

111. The formulation for use of any one of claims 59 to 108, wherein the daily dose is of about 1100 mg to about 1300 mg.

112. The formulation for use of claim 111, wherein the daily dose is of about 1200 mg.


113. The formulation for use of any one of claims 59 to 112, wherein the pharmaceutical oral formulation comprises sodium 2-(3-pentylphenyl)acetate.

114. The formulation for use of any one of claims 59 to 113, wherein the pharmaceutical oral formulation is a capsule or a tablet.

5 115. The formulation for use of any one of claims 59 to 114, wherein the subject has a body mass index (BMI) $\geq 25.0 \text{ kg/m}^2$.

116. The formulation for use of any one of claims 59 to 115, wherein the subject is a male and has a waist circumference $\geq 94 \text{ cm}$, or the subject is a female and has a waist circumference $\geq 80 \text{ cm}$.

1/3

**FIG. 1**

2/3

Week 1




FIG. 2A

Week 24




FIG. 2B

3/3




FIG. 3A




FIG. 3B

INTERNATIONAL SEARCH REPORT

International application No.
PCT/CA2019/051753

A. CLASSIFICATION OF SUBJECT MATTER

IPC: **A61K 31/192** (2006.01), **A61K 9/20** (2006.01), **A61K 9/48** (2006.01), **A61P 3/00** (2006.01), **A61P 3/08** (2006.01), **C07C 57/30** (2006.01)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC: **A61K 31/192** (2006.01), **A61K 9/20** (2006.01), **A61K 9/48** (2006.01), **C07C 57/30** (2006.01)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)

Canadian Patent Database (Intellect), Quetel-Orbit (Fampat), Google Scholar

PBI-4050, ALMS, Alstrom syndrome, sodium 2-(3-pentylphenyl)acetate, oral formulation, histology, glycemic control

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BAIG et al., "Treatment with PBI-4050 in patients with Alström syndrome: study protocol for a phase 2, single-Centre, single-arm, open label trial", <i>BMC Endocrine Disorders</i> 26 November 2018 (26-11-2018), Vol 18(1), pp 88/1-10. https://bmccendocrdisord.biomedcentral.com/articles/10.1186/s12902-018-0315-6 . p. 2, col. 1, para. 3 to p. 2, col. 2, para. 1; p.2, col. 1, para. 1.	1-116
Y	PARKER et al, "PBI-4050 is safe and well tolerated and shows evidence of benefit in idiopathic pulmonary fibrosis", <i>Am J Respir Crit Care Med</i> 00-May 2017 (00-05-2017), 195, A7606. https://www.atsjournals.org/doi/abs/10.1164/ajrccm-conference.2017.195.1_MeetingAbstracts.A7606 . Whole document	1-116

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* "A" "D" "E" "L" "O" "P"	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance document cited by the applicant in the international application earlier application or patent but published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	"T" "X" "Y" "&"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
---	--	--------------------------	--

Date of the actual completion of the international search
27 January 2020 (27-01-2020)

Date of mailing of the international search report
18 February 2020 (18-02-2020)

Name and mailing address of the ISA/CA
Canadian Intellectual Property Office
Place du Portage I, C114 - 1st Floor, Box PCT
50 Victoria Street
Gatineau, Quebec K1A 0C9
Facsimile No.: 819-953-2476

Authorized officer

Yong-Huang Chen (819) 639-0354

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2019/051753

C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	Laurin et al, "PBI-4050 Reduces cardiovascular biomarkers in type II diabetic patients with metabolic syndrome", <i>Circulation</i> 11 November 2016 (11-11-2016), Vol 134(Suppl 1), pp A19469–A19469. https://www.ahajournals.org/doi/10.1161/circ.134.suppl_1.19469 . Whole document	1-116
P, Y	Nasreen Khalil, "Phase 2 clinical trial of PBI-4050 in patients with idiopathic pulmonary fibrosis", <i>Eur Respir J.</i> 19 March 2019 (19-03-2019), Vol 53(3), pp 1-9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422836/pdf/ERJ-00663-2018.pdf .	1-116
A	WO2010127440A1 (PROMETIC BIOSCIENCES INC.) 11 November 2010 (11.11.2010) Compound I, Tables 1, 2; examples 2-7.	1-116
A	WO2010127448A1 (PROMETIC BIOSCIENCES INC.) 11 November 2010 (11-11-2010) Claims 4, 7-9; examples 2-7	1-116
A	US20150313856A1 (PROMETIC BIOSCIENCES INC.) 5 November 2015 (05-11-2015) Compound I, table 2; claim 5.	1-116

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/CA2019/051753

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO2010127440A1	11 November 2010 (11-11-2010)	AU2010244930A1	17 November 2011 (17-11-2011)
		AU2010244930B2	28 July 2016 (28-07-2016)
		AU2011356583A1	09 May 2013 (09-05-2013)
		AU2011356583B2	24 December 2015 (24-12-2015)
		AU2011356583C1	17 March 2016 (17-03-2016)
		AU2016201556A1	14 April 2016 (14-04-2016)
		AU2016201556B2	14 September 2017 (14-09-2017)
		BRPI1015124A2	12 April 2016 (12-04-2016)
		BR112013010507A2	02 August 2016 (02-08-2016)
		CA2761018A1	11 November 2010 (11-11-2010)
		CA2761018C	20 March 2018 (20-03-2018)
		CA2816093A1	26 July 2012 (26-07-2012)
		CL2013001152A1	10 January 2014 (10-01-2014)
		CN102438975A	02 May 2012 (02-05-2012)
		CN102438975B	16 December 2015 (16-12-2015)
		CN103347509A	09 October 2013 (09-10-2013)
		CN103347509B	08 June 2016 (08-06-2016)
		CN105997967A	12 October 2016 (12-10-2016)
		CN105997967B	23 August 2019 (23-08-2019)
		DK2427416T3	13 June 2016 (13-06-2016)
		DK2632452T3	21 January 2019 (21-01-2019)
		EA201171350A1	30 May 2012 (30-05-2012)
		EA022445B1	29 January 2016 (29-01-2016)
		EA201370103A1	30 December 2013 (30-12-2013)
		EA030038B1	29 June 2018 (29-06-2018)
		EA201791585A1	31 May 2018 (31-05-2018)
		EP2427416A1	14 March 2012 (14-03-2012)
		EP2427416A4	03 October 2012 (03-10-2012)
		EP2427416B1	09 March 2016 (09-03-2016)
		EP2632452A1	04 September 2013 (04-09-2013)
		EP2632452A4	07 May 2014 (07-05-2014)
		EP2632452B1	26 September 2018 (26-09-2018)
		EP3443957A1	20 February 2019 (20-02-2019)
		ES2575100T3	24 June 2016 (24-06-2016)
		ES2703257T3	07 March 2019 (07-03-2019)
		HK1169645A1	10 February 2017 (10-02-2017)
		HK1189836A1	10 February 2017 (10-02-2017)
		HUE029126T2	28 February 2017 (28-02-2017)
		IL216006D0	31 January 2012 (31-01-2012)
		IL216006A	31 March 2015 (31-03-2015)
		IL225599D0	27 June 2013 (27-06-2013)
		IL225599A	29 May 2017 (29-05-2017)
		IL251083D0	30 April 2017 (30-04-2017)
		IL251083A	31 July 2018 (31-07-2018)
		JP2015061852A	02 April 2015 (02-04-2015)
		JP5815829B2	17 November 2015 (17-11-2015)
		JP2013544799A	19 December 2013 (19-12-2013)
		JP6007186B2	12 October 2016 (12-10-2016)
		JP2016188247A	04 November 2016 (04-11-2016)
		JP6371344B2	08 August 2018 (08-08-2018)
		JP2012526052A	25 October 2012 (25-10-2012)
		KR20130132448A	04 December 2013 (04-12-2013)
		KR101821646B1	25 January 2018 (25-01-2018)
		KR20180010332A	30 January 2018 (30-01-2018)
		KR101923354B1	28 November 2018 (28-11-2018)
		KR20180011332A	31 January 2018 (31-01-2018)
		KR101943280B1	28 January 2019 (28-01-2019)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/CA2019/051753

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
		KR20120024696A	14 March 2012 (14-03-2012)
		MX2013004832A	22 May 2013 (22-05-2013)
		MX365807B	14 June 2019 (14-06-2019)
		MX2011011757A	25 January 2012 (25-01-2012)
		MX2019007010A	06 September 2019 (06-09-2019)
		MY156780A	31 March 2016 (31-03-2016)
		MY162420A	15 June 2017 (15-06-2017)
		NZ595978A	29 November 2013 (29-11-2013)
		NZ610851A	29 May 2015 (29-05-2015)
		PH12016502324A1	15 July 2019 (15-07-2019)
		PL2427416T3	30 September 2016 (30-09-2016)
		PL2632452T3	29 March 2019 (29-03-2019)
		PT2427416E	15 June 2016 (15-06-2016)
		PT2632452T	10 January 2019 (10-01-2019)
		SG175855A1	29 December 2011 (29-12-2011)
		SG189538A1	28 June 2013 (28-06-2013)
		SG10201807622WA	30 October 2018 (30-10-2018)
		TR201819987T4	21 January 2019 (21-01-2019)
		TW201043601A	16 December 2010 (16-12-2010)
		TWI485134B	21 May 2015 (21-05-2015)
		TW201305097A	01 February 2013 (01-02-2013)
		TW1578983B	21 April 2017 (21-04-2017)
		TW201717928A	01 June 2017 (01-06-2017)
		TWI620563B	11 April 2018 (11-04-2018)
		US2012088784A1	12 April 2012 (12-04-2012)
		US8927765B2	06 January 2015 (06-01-2015)
		US2013217645A1	22 August 2013 (22-08-2013)
		US9114118B2	25 August 2015 (25-08-2015)
		US2015313856A1	05 November 2015 (05-11-2015)
		US9439882B2	13 September 2016 (13-09-2016)
		US2015094372A1	02 April 2015 (02-04-2015)
		US9938221B2	10 April 2018 (10-04-2018)
		US2018162799A1	14 June 2018 (14-06-2018)
		WO2012097427A1	26 July 2012 (26-07-2012)
		ZA201303035B	25 June 2014 (25-06-2014)
WO2010127448A1	11 November 2010 (11-11-2010)	AU2010244938A1	17 November 2011 (17-11-2011)
		BRPI1015118A2	12 April 2016 (12-04-2016)
		CA2761061A1	11 November 2010 (11-11-2010)
		CN102421742A	18 April 2012 (18-04-2012)
		CN102421742B	06 August 2014 (06-08-2014)
		DK2427417T3	20 January 2014 (20-01-2014)
		EP2427417A1	14 March 2012 (14-03-2012)
		EP2427417A4	26 September 2012 (26-09-2012)
		EP2427417B1	09 October 2013 (09-10-2013)
		ES2441800T3	06 February 2014 (06-02-2014)
		HK1169379A1	24 July 2015 (24-07-2015)
		JP2012526053A	25 October 2012 (25-10-2012)
		JP5844251B2	13 January 2016 (13-01-2016)
		KR20120090011A	16 August 2012 (16-08-2012)
		MX2011011756A	25 January 2012 (25-01-2012)
		PL2427417T3	31 March 2014 (31-03-2014)
		PT2427417E	13 January 2014 (13-01-2014)
		TW201043226A	16 December 2010 (16-12-2010)
		TWI458481B	01 November 2014 (01-11-2014)
		US2012095102A1	19 April 2012 (19-04-2012)
		US8637574B2	28 January 2014 (28-01-2014)
US2015313856A1	05 November 2015 (05-11-2015)	US9439882B2	13 September 2016 (13-09-2016)
		AU2010244930A1	17 November 2011 (17-11-2011)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2019/051753

AU2010244930B2	28 July 2016 (28-07-2016)
AU2011356583A1	09 May 2013 (09-05-2013)
AU2011356583B2	24 December 2015 (24-12-2015)
AU2011356583C1	17 March 2016 (17-03-2016)
AU2016201556A1	14 April 2016 (14-04-2016)
AU2016201556B2	14 September 2017 (14-09-2017)
BRPI1015124A2	12 April 2016 (12-04-2016)
BR112013010507A2	02 August 2016 (02-08-2016)
CA2761018A1	11 November 2010 (11-11-2010)
CA2761018C	20 March 2018 (20-03-2018)
CA2816093A1	26 July 2012 (26-07-2012)
CL2013001152A1	10 January 2014 (10-01-2014)
CN102438975A	02 May 2012 (02-05-2012)
CN102438975B	16 December 2015 (16-12-2015)
CN103347509A	09 October 2013 (09-10-2013)
CN103347509B	08 June 2016 (08-06-2016)
CN105997967A	12 October 2016 (12-10-2016)
CN105997967B	23 August 2019 (23-08-2019)
DK2427416T3	13 June 2016 (13-06-2016)
DK2632452T3	21 January 2019 (21-01-2019)
EA201171350A1	30 May 2012 (30-05-2012)
EA022445B1	29 January 2016 (29-01-2016)
EA201370103A1	30 December 2013 (30-12-2013)
EA030038B1	29 June 2018 (29-06-2018)
EA201791585A1	31 May 2018 (31-05-2018)
EP2427416A1	14 March 2012 (14-03-2012)
EP2427416A4	03 October 2012 (03-10-2012)
EP2427416B1	09 March 2016 (09-03-2016)
EP2632452A1	04 September 2013 (04-09-2013)
EP2632452A4	07 May 2014 (07-05-2014)
EP2632452B1	26 September 2018 (26-09-2018)
EP3443957A1	20 February 2019 (20-02-2019)
ES2575100T3	24 June 2016 (24-06-2016)
ES2703257T3	07 March 2019 (07-03-2019)
HK1169645A1	10 February 2017 (10-02-2017)
HK1189836A1	10 February 2017 (10-02-2017)
HUE029126T2	28 February 2017 (28-02-2017)
IL216006D0	31 January 2012 (31-01-2012)
IL216006A	31 March 2015 (31-03-2015)
IL225599D0	27 June 2013 (27-06-2013)
IL225599A	29 May 2017 (29-05-2017)
IL251083D0	30 April 2017 (30-04-2017)
IL251083A	31 July 2018 (31-07-2018)
JP2015061852A	02 April 2015 (02-04-2015)
JP5815829B2	17 November 2015 (17-11-2015)
JP2013544799A	19 December 2013 (19-12-2013)
JP6007186B2	12 October 2016 (12-10-2016)
JP2016188247A	04 November 2016 (04-11-2016)
JP6371344B2	08 August 2018 (08-08-2018)
JP2012526052A	25 October 2012 (25-10-2012)
KR20130132448A	04 December 2013 (04-12-2013)
KR101821646B1	25 January 2018 (25-01-2018)
KR20180010332A	30 January 2018 (30-01-2018)
KR101923354B1	28 November 2018 (28-11-2018)
KR20180011332A	31 January 2018 (31-01-2018)
KR101943280B1	28 January 2019 (28-01-2019)
KR20120024696A	14 March 2012 (14-03-2012)
MX2013004832A	22 May 2013 (22-05-2013)
MX365807B	14 June 2019 (14-06-2019)
MX2011011757A	25 January 2012 (25-01-2012)
MX2019007010A	06 September 2019 (06-09-2019)
MY156780A	31 March 2016 (31-03-2016)
MY162420A	15 June 2017 (15-06-2017)

INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2019/051753

NZ595978A	29 November 2013 (29-11-2013)
NZ610851A	29 May 2015 (29-05-2015)
PH12016502324A1	15 July 2019 (15-07-2019)
PL2427416T3	30 September 2016 (30-09-2016)
PL2632452T3	29 March 2019 (29-03-2019)
PT2427416E	15 June 2016 (15-06-2016)
PT2632452T	10 January 2019 (10-01-2019)
SG175855A1	29 December 2011 (29-12-2011)
SG189538A1	28 June 2013 (28-06-2013)
SG10201807622WA	30 October 2018 (30-10-2018)
TR201819987I4	21 January 2019 (21-01-2019)
TW201043601A	16 December 2010 (16-12-2010)
TWI485134B	21 May 2015 (21-05-2015)
TW201305097A	01 February 2013 (01-02-2013)
TWI578983B	21 April 2017 (21-04-2017)
TW201717928A	01 June 2017 (01-06-2017)
TWI620563B	11 April 2018 (11-04-2018)
US2012088784A1	12 April 2012 (12-04-2012)
US8927765B2	06 January 2015 (06-01-2015)
US2013217645A1	22 August 2013 (22-08-2013)
US9114118B2	25 August 2015 (25-08-2015)
US2015094372A1	02 April 2015 (02-04-2015)
US9938221B2	10 April 2018 (10-04-2018)
US2018162799A1	14 June 2018 (14-06-2018)
WO2010127440A1	11 November 2010 (11-11-2010)
WO2012097427A1	26 July 2012 (26-07-2012)
ZA201303035B	25 June 2014 (25-06-2014)